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Abstract 
 
INTRODUCTION: Substance P (SP) has well-established roles in 
neurogenic inflammation and pain transmission, however recently, a 
number of SP immunomodulatory effects have been shown. In this thesis 
SP and its neurokinin-1-receptor (NK1R) role in autoimmune 
inflammation was investigated with an applicability to multiple sclerosis 
(MS). In the four experimental chapters the role of SP and its receptor was 
studied in human immune cells and neurons with a focus on the 
relationship with Th17 and Th1 pathways as the main pro-inflammatory 
arms in autoimmune pathology. 
 
AIMS: To quantify the effects of SP on inflammatory cytokine induction 
in peripheral blood mononuclear cells (PBMC); to measure Th17 and Th1 
pathway effects on SP and NK1R expression in T cells and NT2 neurons; 
to compare NK1R expression and relevant parameters in peripheral 
immune cells of relapsing-remitting MS patients and healthy controls. 
 
METHODS: Real-time PCR, flow cytometry, ELISA, Western blotting 
and promoter studies were used to measure the expression of target genes 
under different stimulation conditions. Cells were isolated from consented 
healthy controls, relapsing-remitting MS patients, or differentiated as 
specified. 
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RESULTS: In PBMC, treatment with SP significantly increased the 
relative quantity of IL-12/IL-23 subunit p40, IL-23 p19 and IL-12 p35 
mRNA showing that SP can signal induction of IL-12 and IL-23. As part 
of the reciprocal mechanism in T cells, NK1R and SP expression was 
strongly upregulated by Th17 cytokines and significantly less by Th1 
cytokines. These effects for NK1R were confirmed at promoter and 
protein levels. The Th17 effects were prevalent at earlier stages compared 
to the Th1 effects. As a novel finding, IL-17 (IL-17A) had direct effects 
on neurons via its functionally expressed receptor. Neuronal NK1R 
mRNA-level expression was subject to regulation by IL-17, whereas SP 
precursor was considerably less upregulated by IL-17. In MS patients in a 
relapse NK1R mRNA in peripheral immune cells was strongly 
downregulated as compared to controls. This finding is likely associated 
with the inflammatory activity in an acute MS relapse. 
 
CONCLUSIONS: Mutual interactions exist between SP and Th17, Th1 
responses with SP showing involvement in Th17 and less in Th1 pathway 
effects. This supports NK1R role in mediating autoimmune activity as 
occurs in an acute MS relapse. The results also show direct neuronal 
involvement in immune interactions involving SP and Th17 pathway.
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1 Introduction 
 
Substance P (SP) belongs to one of the largest and most abundantly found 
peptide families within a living organism, known as tachykinins (TKs). SP 
has been mainly regarded as a neuropeptide present both in the central 
nervous system (CNS) as well in peripheral nerves. It has a well-
established role in pain transmission and neurogenic inflammation, 
including effects of vasodilatation and plasma extravasation. With its 
effects on smooth muscle, SP is known to be involved in motility of 
different organ tracts as well as stimulation of glandular secretion and 
modulating autonomic reflexes (Harrison et al. 2001; Hokfelt et al. 2001). 
 
Recently, however, its conventional meaning as a neuropeptide has been 
challenged as SP has been found in various non-neuronal cells and having 
a role in intercellular signalling. Its expression particularly in immune cells, 
such as lymphocytes, macrophages, dendritic cells, eosinophils and its 
immunoregulatory effects on them have caused it to be rather characterized 
as an immunomodulatory neuropeptide (O'Connor et al. 2004). Along with 
other neuropeptides, SP is found to be involved in neuroimmune 
interactions revealing increasing overlap between these systems as well as 
challenging definitions of a neurotransmitter and a cytokine (Reinke et al. 
2006; Franco et al. 2007; Levite 2008). 
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SP acts primarily via neurokinin-1 receptor (NK1R) and exerts its 
inflammatory activity with various effects on immune cells. It has been 
shown to stimulate lymphocyte proliferation and antibody production, 
inflammatory cytokine secretion in immunocytes and release of various 
other inflammatory agents, including oxygen free radicals, arachidonic 
acid metabolites and histamine from these cells (Harrison et al. 2001). Via 
release of these mediators or by SP directly inflammatory effects of SP are 
implemented. 
  
In addition to SP role in various neurogenic inflammatory conditions, its 
involvement has been shown in a number of primarily immunogenic 
inflammatory diseases. Elevated levels of SP and upregulated NK1R have 
been reported in inflammatory bowel disease and rheumatoid arthritis 
(O'Connor et al. 2004). There is evidence of its role in multiple sclerosis 
(MS) murine model experimental autoimmune encephalomyelitis (EAE), 
showing suppression of the disease by NK1R antagonists and in NK1R 
knockout phenotype (Nessler et al. 2006; Reinke et al. 2006). In humans, 
SP-immunoreactive astrocytes have been found in MS lesions, suggesting 
SP role in MS lesion formation (Kostyk et al. 1989). Additionally, SP 
precursor encoding TAC1 gene has been highlighted in genome-wide 
linkage studies as a possible susceptibility gene for MS (Vandenbroeck et 
al. 2002; Cunningham et al. 2005). 
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SP is a widely expressed peptide with a variety of functions yet only a few 
of them have been clearly characterized. The modulating role of SP in 
autoimmune inflammation still remains largely unknown, particularly with 
regards to the recently uncovered Th17 pathway. Moreover, SP 
interactions with the pro-inflammatory Th1 and Th17 pathways have not 
been investigated in humans. The roles and regulatory potential of SP in 
inflammation within the CNS, where it is abundantly expressed, is also 
poorly understood. Very little is known to date about its messenger role in 
neuroimmune intersystem communication. 
 
Resulting from above, the current thesis focuses on the role of this peptide 
in immunogenic inflammation, with an emphasis on MS. In the literature 
review topics on SP and MS will be covered. Further information on Th1 
and Th17 pathways, different cell types and interactions relevant to the 
thesis is provided in individual chapter introductions. In the following 
literature review all the effects are referred to the human species, unless 
indicated differently.  
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2 Literature Review 
2.1 Substance P and its receptor 
2.1.1 Historical background 
SP was first described in alcoholic extracts of equine brain and intestine by 
von Euler and Gaddum in 1931 (Hokfelt et al. 2001; Severini et al. 2002) 
and was found to have potent hypotensive and smooth muscle contractile 
properties (Euler et al. 1931). Gaddum and Schild (Gaddum et al. 1934) 
QDPHGWKHQHZDJHQWVXEVWDQFH3UHIHUULQJWR WKH³3UHSDUDWLRQ´REWDLQHG
after the extraction procedure (Page 2004). It was first postulated by 
Lembeck that SP could function as a neurotransmitter associated with pain 
transmission as it was found in high concentrations in dorsal roots of the 
spinal cord (Harrison et al. 2001). Otsuka and Konishi (Otsuka et al. 1976) 
showed later that SP immunoreactivity increased in the perfusate taken 
from isolated spinal cord of newborn rats after application of electrical 
stimuli.  
 
The amino acid (aa) sequence of SP was determined by Chang and Leeman 
in 1970 (Lecci et al. 2006). It was found to be an undecapeptide having the 
following sequence Arg1-Pro2-Lys3-Pro4-Gln5-Gln6-Phe7-Phe8-Gly9-Leu10-
Met11-NH2 (Harrison et al. 2001) (Fig 2.1). 
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Figure 2.1. Chemical structure of SP with a molecular formula 
C63H98N18O13S and a molecular weight 1347.63 g/mol (Substance P 
Compound Summary - CID 36511, 2010) (PubChem 2010). 
 
Later SP was classified as part of the tachykinin (TK) family having over 
40 members identified in vertebrates and invertebrates (Severini et al. 
2002). In addition to SP, currently known human TKs include neurokinin 
A (NKA) with its elongated forms neuropeptide K (NPK) and 
neuropeptide-J (NPJ), neurokinin B (NKB), and more recently identified 
human hemokinin-1 (hHK-1) with its two known elongated forms 
endokinin A (EKA) and EKB (Lecci et al. 2006). 
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2.1.2 Chemical properties of SP 
SP conformation appears to be strongly dependent upon the solvent. For 
LQVWDQFH LQ PHWKDQRO WKH VWUXFWXUH FRQWDLQV WKH PLFWXUH RI ȕ-turn 
conformations, whereas in water there is an extended chain structure 
(Sumner et al. 1990). The following features appear to be characteristic of 
63LQDOOPHGLDĮ-helical core from Pro4 to Phe8 which is stabilized by two 
hydrogen bonds between Phe7-NH/Lys3-CO, Phe8-NH/Pro4-CO; an 
extended highly flexible N-terminal Arg1-Pro2-Lys3; and a central turn on 
the Gly9, bringing the C-WHUPLQDODPLGHLQFRQWDFWZLWKWKHȖ-carbonyl O-
atom of both of the glutamines (Lavielle et al. 1988; Regoli et al. 1994).  
 
By definition TKs all share the same conserved hydrophobic C-terminal 
region, Phe-X-Gly-Leu-Met-NH2, where X is always hydrophobic, that is 
either an aromatic or a E-branched aliphatic amino acid (Page 2004). 
Aromatic phenylalanine or tyrosine in this location is considered indicative 
of NK1R binding affinity (Page 2004). In contrast, at their N-terminals 
they possess divergent and hydrophilic regions believed to convey receptor 
specificity (Ingi et al. 1991). The C-terminal end of SP is naturally 
amidated without which a great deal of SP activity is lost. This has been 
explained mainly due to its ionicity (negative charge) near physiological 
pH, amide hydrogen involvement in conformational interactions, and lack 
of stability i.e. toward different peptidases and synthetases (Escher et al. 
1982).  
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Due to methionine residue, SP is very susceptible to oxidation. In aqueous 
solutions SP quickly looses its activity. For storage in liquid form it is 
advised to keep it at acidic pH (e.g. 0.05 M acidic acid) or by using oxygen 
free water (Sigma 1998). Addition of bovine serum albumine (1%) 
increases solution stability. Crude solutions are stable below pH 8 but are 
rapidly destroyed above pH 8 (Merck 1989). Solutions are advised to be 
stored frozen at -20 to -70 C in small aliquots with repeated freeze-thaw 
cycles avoided (Sigma 1998). 
 
2.1.3 Expression of SP 
SP is expressed widely in the central and peripheral nervous system and 
beyond. SP is produced by several cell types, including neurons, astrocytes, 
microglia (Michel et al. 1986; Barker et al. 1992) as well as endothelial 
cells (Barker et al. 1992) and lymphocytes (Lai et al. 1998), monocytes, 
macrophages (Ho et al. 1997), eosinophils (Metwali et al. 1994) and 
endocrine cells (Page 2004). In the CNS, SP immunoreactivity has been 
shown in a wide variety of structures also developmentally, including 
telencephalon, basal ganglia, hippocampus, amygdala, septal areas, 
hypothalamus, mesencehalon, metencephalon, myelencephalon, spinal 
cord (Shults et al. 1984; Lee et al. 1985). For example, SP fibres 
originating in the striatum and projecting in the midbrain have been shown 
to modulate the activity of dopaminergic neurons (Reid et al. 1990; Chen 
et al. 2004). SP is present in dorsal root ganglia and sensory nerves, 
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mediating pain transmission, and both in central and peripheral 
components of the autonomic systems (Dun et al. 1981). The recently 
discovered EKA/B, that may crosstalk with SP, are abuntantly expressed in 
peripheral non-neuronal tissues (Page 2004). 
 
2.1.4 Genetics of SP 
Three genes encoding TKs have been identified in humans: TAC1 (or 
PPT-I or PPT-A), TAC3 (or PPT-II or PPT-B) and TAC4 (or PPT-C) (Tab 
2.1). TAC1 consists of seven exons, the sequence that encodes SP is 
contained in exon 3. Alternative splicing of TAC1 transcript gives four 
distinct D, E, J and G forms of messenger ribonucleic acid (mRNA) (Fig 
2.2). D-TAC1 and G-TAC1 encode SP, E-TAC1 encodes SP, NKA and 
NPK, and J-TAC1 encodes SP, NKA and NPJ (Nawa et al. 1984). The 
most frequently expressed isoforms of TAC1 mRNA in human T cells has 
been shown to be E and J isoforms in healthy subjects (Cantalupo et al. 
2008). A relative shift in E/J ratio has been shown in MS patients in a 
relapse (Cantalupo et al. 2008).  
 
The TAC3 gene transcribes three forms of mRNA (D, E, J) of which only 
the D- and E-TAC3 are translated into NKB (Hokfelt et al. 2001). The 
TAC4 gene can be transcribed into D, E, J and G mRNA isoforms of which 
the D one has two variants: D-TAC4v1, encoding EKA and EKC, and D-
TAC4v2 encoding EKB and EKC. 
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Figure 2.2. Schematic diagram showing combinations of exons in alternative 
splicing of TAC1 transcripts. The numbers refer to the same exons encoding 
four different forms of mRNA. 
 
 
The EKC has a C-terminal Leu-NH2 and cannot be properly considered a 
TK. It also lacks significant activity at TK receptors. The E-TAC4 mRNA 
is translated into EKB and EKD, the latter which like EKC, has a modified 
C-terminal sequence. Both J- and G-TAC4 code for EKB only (Page 2004). 
 
SP is released from its precursor by the actions of proteases called 
convertases. Cleavage points for the convertases on the SP precursor are 
doublets of cationic residues (Harrison et al. 2001). Typical cleavage 
points are Lys-Arg, Arg-Arg, and Arg-Lys doublets (Steiner et al. 1992). 
This is followed by C-terminal amidation by the action of peptidyl-Gly-Į-
amidating monoxygenase (Lembeck 1953). 
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Gene Chromosome 
position 
mRNA 
transcript 
cDNA 
transcript 
length 
(bp) 
Precursor 
protein 
length (aa) 
Peptides 
predicted on 
precursor 
Accession 
number 
TAC1 7q21-q22 DTAC1 1048 111 SP NM_013996 
  ETAC1 1102 129 SP,NKA, 
NPJ 
NM_003182 
  JTAC1 1057 114 SP,NKA, 
NPK 
NM_013997 
  GTAC1 1003 96 SP NM_013998 
TAC3 12q13-q21 DTAC3 902 135 NKB AF537115 
  ETAC3 785 121 NKB AF537118 
  JTAC3 731 103 NA AF537121 
TAC4 17q21.33 TAC4 225 68 hHK-1, 
hHK-1(4-
11) 
AF521560 
  DTAC4v1 675 113 EKA, EKC AF515828 
  DTAC4v2 657 107 EKB, EKC AY471574 
  ETAC4 624 96 EKB, EKD AF515829 
  JTAC4 597 87 EKB AF515830 
  GTAC4 564 76 EKB AF515831 
 
Table 2.1. Human tachykinins (adapted from Page NM, 2004). 
 
2.1.5 SP synthesis and metabolism 
In neuronal cells synthesis of SP occurs in ribosomes and is confined to the 
pericaryon (Harmar et al. 1980). SP is then packed into storage vesicles 
(Plenderleith et al. 1990) and transported axonally to terminal endings for 
final enzymatic processing (Brimijoin et al. 1980). SP seems to be the most 
easily inactivated by proteolytic enzymes compared to other tachykinins 
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(Severini et al. 2002). A number of enzymes seem to be involved in the 
metabolism of SP, including: neutral endopeptidase (NEP), SP-degrading 
enzyme (SP-DE), angiotensin-converting enzyme (ACE), dipeptidyl-
aminopeptidase IV (DPIV), post-proline endopeptidase (PEP), cathepsin-D 
and cathepsin-E. Although all of these enzymes cleave SP in vitro, due to 
their specific cellular localization it is probably NEP and ACE that are 
most commonly involved in the cleavage of SP in the periphery (Nadel 
1991). NEP has been demonstrated to be involved in the metabolism of SP 
in the brain (Hooper et al. 1987), spinal cord (Sakurada et al. 1990) and in 
peripheral tissues (Di Maria et al. 1998), whereas ACE is known to 
degrade SP in plasma (Wang et al. 1991) and cerebrospinal fluid (Harrison 
et al. 2001). Both NEP and ACE catalyze the hydrolysis of Phe8-Gly9 or 
Gly9-Leu10 bonds of SP, leaving the peptide lacking the C-terminal regions 
required to bind to the tachykinin receptors (Skidgel et al. 1987). The N-
terminal fragments of SP, particularly SP (1-4) (Joshi et al. 2001) and SP 
(1-7) (Zhou et al. 2002) are biologically active SP metabolites and the 
formation of these products can be blocked by the action of specific 
endopeptidase inhibitors (Sakurada et al. 1999). 
 
2.1.6 TK receptors 
TKs exert their effects on target cells through the TK receptor family. 
These receptors consist of seven hydrophobic transmembrane domains, 
connected by extra- and intracellular loops and coupled to G-proteins 
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(Regoli et al. 1989; Gerard et al. 1991; Gerard et al. 1993). There are three 
main types of neurokinin receptors NK1, NK2 and NK3 exhibiting 
preferences for substance P, neurokinin A and neurokinin B respectively 
(Regoli et al. 1994). In summary, the affinities of these peptides as ligands 
to NK1 receptor (NK1R) can be expressed as follows: SP>NKA>NKB, 
that to NK2R as NKA>NKB>SP and to NK3R as NKB>NKA>SP 
(Harrison et al. 2001). All TKs show some degree of cross-reactivity 
among TK receptors as their affinity is dictated by common C-terminal 
amino acid (aa) sequence. 
 
Two isoforms of NK1R exist in humans with a different length of the C-
terminal end: a full-length NK1R (also referred to as NK1R-F) consisting 
of 407 aa (Fig 2.3) and a truncated isoform NK1R-T consisting of 311 aa 
(Fong et al. 1992; Lai et al. 2008; Chernova et al. 2009). The latter has 
been found in peripheral tissues whereas NK1R is abundant in the CNS 
(Caberlotto et al. 2003; Lai et al. 2008) ,Q WKLV WKHVLV ³1.5´KDVEHHQ
used to refer to NK1R-F. 
 
It has been shown for NK1R that the receptor can be easily internalised, 
helping to regulate the receptor response e.g. after noxious stimuli and SP 
binding; its density on a cell membrane can be restored quickly (on 
average within 30 min) after a stimulus (Mantyh et al. 1995). 
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Figure 2.3. Diagram of human full-length NK1R with a relative molecular 
mass of 46 kDa. The second and third transmembrane (TM) domains are 
involved in agonist/antagonist binding, the third cytoplasmic loop is 
responsible for G-protein interaction. Roman numerals indicate the number 
of TM domains, E1-3 and C1-3 designate extracellular and cytoplasmic loops 
UHVSHFWLYHO\DGDSWHGIURP2¶&RQQRUHWDO 
 
Different conformations for NK1R and NK2R have been demonstrated that 
may be conditioned by the ligand with subsequent activation of different 
G-proteins (Palanche et al. 2001). 
 
2.1.7 Genetics of TK receptors 
The gene for NK1R, TACR1, is located on human chromosome 2, spans 
45-60 kb and is contained in 5 exons (Gerard et al. 1991). The gene is 
known to provide two splice variants that differ in the length of the 
cytoplasmic C-terminal tail by approximately 8 kDa (Li et al. 1997). The 
long isoform of NK1R, prevalent in the brain, and the truncated isoform, 
I 
E1 E2 E3 
C1 C2 
VII 
C3 
II III IV V VI 
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mainly in peripheral tissues (Caberlotto et al. 2003), show differences in 
the signal transduction and desensitisation rates (Li et al. 1997).  
 
NK2R encoding gene TACR2 also yields two splice variants: the D-
LVRIRUPLVWKH³FODVVLF´1.5ZKHUHDVWKHE-isoform lacks the long amino 
acid sequence forming E III and C II loops and a TM domain IV (Lecci et 
al. 2006). TKs have not been found to bind to this receptor isoform, 
however, other ligands have not been described (Lecci et al. 2006). The 
gene encoding NK3R has been defined as TACR3, the claimed existence 
of NK3R subtypes has not been confirmed (Lecci et al. 2006). 
 
2.1.8 Receptor binding and signalling 
The C-terminal region is central to the activation of each of the three TK 
receptors (Page 2004). Radiolabelled mapping and mutagenesis studies 
have shown that SP inserts itself into the hydrophobic ligand binding 
pocket (TM II, III and VII) between the transmembrane domain and 
extracellular surface and the centre bilayer (Huang et al. 1994; Rosenkilde 
et al. 1994). The remainder of the SP molecule interacts with amino acids 
on the extracellular surface of the receptor. (Fig 2.4) 
 
Human NK1R has been found to stimulate multiple second messenger 
systems and to couple to several members of the G- protein family (Gq/11, 
*ĮV*Į(Macdonald et al. 1996; Roush et al. 1998).  G-proteins  are  
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Figure 2.4.  Diagrams of the human NK1R binding of SP and the non-peptide 
antagonist CP-96345. The upper diagram shows the extracellular part of the 
receptor from an outside-inward view and the lower diagram depicts 
transectional view through the cell membrane. Residues suggested to be 
involved in SP binding are shown in white on black (TM domains II, III and 
VII), residues involved in CP-96345 binding are shown in black on grey (TM 
V and VI). Although the binding sites are spatially different the binding is 
competitive due to interchange in allosteric conformations of the receptor 
(Rosenkilde et al, 1994). 
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coupled to the third cytoplasmic loop of the NK1R (O'Connor et al. 2004). 
Upon receptor-ligand interaction conformational changes within the 
receptor cause exchange of guanosine diphosphate (GDP) with guanosine 
triphosphate (GTP) that activates the attached G-protein. The D subunit of 
the G-protein dissociates from the E and J subunits and activates the 
intracellular effectors (Khawaja et al. 1996), such as members of the 
mitogen-activated protein kinase (MAPK) cascade, including extracellular 
signal-regulated kinases 1 and 2 (ERK1/2) and p38MAPK (DeFea et al. 
2000; Fiebich et al. 2000). ERK1/2 translocate into the nucleus and 
mediate phosphorylation of transcription factors such as NFNB, widely 
involved in cytokine expression (Lieb et al. 1997; Tokuda et al. 2005). 
p38MAPK subfamily comprises kinases functioning as a signal tranduction 
pathway independent of NFNB. This pathway also has been shown to 
mediate SP-induced inflammatory cytokine expression, such as IL-6 
(Fiebich et al. 2000). 
 
Another effector of G-protein activation is phospholipase CE (PLCE) that 
hydrolyses phosphatidyl inositol biphosphate (PIP2) into two second 
messenger molecules inositol triphosphate (IP3) and diacylglycerol (DAG).  
IP3 acts on specific receptors to release intracellular stores of calcium from 
the sarcoplasmic reticulum. DAG acts via protein kinase C (PKC) to open 
calcium channels in the plasma membrane. The increase in [Ca2+] leads to 
the tissue responses. One of such NK1R mediated responses dependent on 
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PKC activation and extracellular calcium is arachidonic acid release 
(Garcia et al. 1994). 
 
TK receptor activation can be coupled via G-proteins also to adenylyl 
cyclase activation (Khawaja et al. 1996) that converts ATP into cAMP. 
The second messenger cAMP acts via different effectors and is able to 
inhibit the proliferation of many cell types but stimulate proliferation of 
others. The mechanisms for this differential regulation involve cross-talk 
between different signalling pathways (Dumaz et al. 2005). 
 
NK1R-T has not been shown to induce Ca2+ mobilisation independently, 
but as a result of crosstalk with co-receptor mediated responses, such as 
chemokine receptor CCR5. ERK1/2 pathway has been suggested in NK1R-
T downstream signalling (Chernova et al. 2009). 
 
2.1.9 Receptor agonists 
Natural agonists for neurokinin receptors are relatively nonselective, 
examples include aforementioned members of the TK family. In 
developing synthetic agonists, modifications in amino acid sequences of 
the parent peptide have been used, particularly at the common C-terminal. 
(Regoli et al. 1989). Several selective synthetic agonists have resulted 
([pGlu6,Pro9]SP(6-11), [Sar9Met(O2)11]SP, [Nle10]NKA(4-10), 
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[MePhe7]NKB etc) that have been used in characterizing the neurokinin 
receptors and elucidating their physiological function (Regoli et al. 1989). 
 
2.1.10 NK1R antagonists 
Antagonists for the SP receptor were first recognised in 1960s with 
analogues of nonmammalian TK eledosin, containing a D-amino acid 
(Schroder et al. 1964). Resulting from this, several other peptide 
antagonists were synthesized that lacked oral bioavailability and 
penetration into the CNS (Harrison et al. 2001). 
 
A beakthrough was observed with NK1R antagonists following the 
discovery of CP-96345 (Snider et al. 1991), the first non-peptide 
tachykinin receptor (NK1R) antagonist (Fig 2.5).  
 
 
 
Figure 2.5. CP-96345, chemically as (2S,3S)-cis-2-(diphenylmethyl)-N-([2-
methoxyphenyl]-methyl)-1-azabicyclo(2.2.2)-octan-3-amine. 
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Both CP-96345 and CP-99994 (another NK1 selective antagonist) readily 
crossed the BBB (Snider et al. 1991). These compounds contained a benzyl 
group with an ortho- (and ortho-methoxy-) substitution on the benzyl ring 
which enhanced the binding and affinity for the receptor (Lowe et al. 1992).  
 
Additional non-peptide NK1R antagonists have been synthesized, such as 
RP-67580 or SR-140333 (Emonds-Alt et al. 1993). It is noteworthy, that 
many of the selective NK1R antagonists demonstrate species-related 
variation in affinity. CP-96345 is a more potent antagonist in human, 
guinea-pig and rabbit tissue, whilst RP-67580 is a better antagonist in rat 
and mouse preparations (Snider et al. 1991). These slight variations are 
often linked to the change of a single mutation of the amino-acid sequence 
of the receptor (Harrison et al. 2001). 
 
Binding sites for these competitive nonpeptide antagonists and SP have 
been analyzed. It was discovered that the peptide is binding at the 
extracellular ends of the transmembrane helices and especially in the 
extracellular loops of the receptor, whereas the small hydrophobic, 
nonpeptide antagonists are binding more deeply inbetween the 
transmembrane segments. CP-96345 has been shown to interact 
specifically with residues 183-196 (TM V) and 271-276 (TM VI) (Gether 
et al. 1993), a glutamine residue 165 (TM IV) (Fong et al. 1994), and 
histidine 265 (TM VI) of NK1R (Zoffmann et al. 1993). There appears to 
be very little overlap in the binding sites for CP-96345 and SP, although 
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they are competitive binders (Fig 2.4). This is due to these receptors 
functioning as allosteric molecules, where agonists and antagonists are 
believed to stabilize different conformations (Hokfelt et al. 2001).  
 
Several other selective NK1R antagonists have been derived, some of 
which have been successful in clinical trials. MK-869 is an orally available 
and long-acting NK1R antagonist which have been shown useful in major 
depressive disorders (Kramer et al. 1998), CP-99994 ameliorating post-
operative pain after dental extraction (Dionne et al. 1998) and L-7540303 
having anti-emetic effects (Harrison et al. 2001). 
 
2.1.11  SP and neurogenic inflammation 
The function of SP and other neuropeptides in sensory nerves is not 
confined to mediating sensation. TK-containing sensory nerves innervate 
most of the organs, including the viscera, and are highly represented also 
near cerebral arteries (Edvinsson et al. 1983). Neuropeptides can be 
released from these nerves in response to noxious and inflammatory 
stimuli (Oku et al. 1987). The immediate effects of SP, released from the 
peripheral nerve endings, are particularly prominent on the vasculature 
where SP induces vasodilatation of the arterioles (together with calcitonin 
gene-related peptide, CGRP) (Fiscus et al. 1992), plasma extravasation in 
post-capillary venules (entirely mediated by tachykinins) (Piedimonte et al. 
1993) and leukocyte adhesion to endothelial cells of venules (Nakanishi 
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1987). SP stimulates mast cells and basophils to release histamine and 
other mediators, such as leukotriens (Harrison et al. 2001), whose releasing 
activity of SP can further contribute to plasma extravasation and oedema 
(Severini et al. 2002). The consequence of neurogenic inflammation is also 
pain and that can positively feedback the above effects (Severini et al. 
2002). 
 
2.1.12 SP in immunogenic inflammation 
Bi-directional effects as above are responsible also for 
neuroimmunoregulatory interactions. TK-containing afferent nerve fibres 
innervate immune organs and tissues, including thymus, spleen, bone 
marrow and lymph nodes (Severini et al. 2002; Steinman 2004). This can 
provide means via which neural control over immune responses is 
maintained. TK receptors in these tissues indicate receptive function and 
are present on most immune cells. Importantly, immune cells themselves 
express SP and other neuropeptides and their receptors (Levite 2008).  
 
Immunoregulatory effects of neuropeptides are exerted to a great extent 
through their modulation of cytokine production by different types of cells. 
SP has been shown to stimulate cytokine secretion including IL-1, IL-6, 
IL-8, IL-10, IL-12, TNF-D from monocytes and macrophages (Lotz et al. 
1988; Laurenzi et al. 1990; Ho et al. 1996; Kincy-Cain et al. 1997), IL-2, 
IFN-J, IL-4 and IL-10 from T cells (Calvo et al. 1992; Blum et al. 1993). 
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SP has been shown to stimulate inflammatory cytokine IL-6 and IL-1 
production also in astrocytes and microglia (Martin et al. 1992; Martin et al. 
1993; Gitter et al. 1994; Lieb et al. 1998). IL-12 induction by SP has not 
been investigated in humans (except for our preliminary results) and the 
relationship between SP and IL-23 has previously not been investigated.  
 
The indirect effect of IL-12 on IFN-J production could conceivably be 
mediated by SP. In murine models, IL-12 has been shown to induce SP 
precursor mRNA in macrophages via STAT4 pathway (Arsenescu et al. 
2005) and NK1R expression by both IL-12 and IL-18 stimulation via 
NFNB (Weinstock et al. 2003). Recently, IL-12 and IL-23 have been found 
to induce SP synthesis in murine T cells and macrophages which can be 
regulated by IL-10 and TGF-ȕ respectively (Blum et al. 2008). In turn, SP 
enhances IFN-J production in different inflammatory models (Blum et al. 
1993; Blum et al. 2001) and as part of the IL-12 immune regulatory circuit 
may be important in promoting Th1 responses (Arsenescu et al. 2005).  
 
Other effects of SP include stimulating proliferation of T and B cells 
(Raffa 1998). SP is known to act as a B cell differentiation co-factor and 
have effects on immunoglobulin production (Bost et al. 1992). SP 
enhances cell-mediated cytotoxicity of Tc and natural killers (Wozniak et 
al. 1993) as well as phagocytosis in macrophages (Bar-Shavit et al. 1980). 
It induces oxidative burst in macrophages with release of oxygen radicals, 
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arachidonic acid derivatives that are involved in tissue injury and indirectly 
stimulate recruitment of immune cells (Raffa 1998).  
 
The mechanisms of chemotaxis by SP are not clear; evidence exists that 
chemotactic activity may reside in its C-terminal amino acid sequence 
(O'Connor et al. 2004). Loss of chemoattractant effect of SP on neutrophils 
has been described in NK1R knock-out mice (Ahluwalia et al. 1998). SP 
has been also found to induce macrophage inflammatory protein-1E 
expression in human T cells (Guo et al. 2002). Lately, it has been found 
that SP promotes CCR5-mediated chemotaxis of human monocytes. This 
has been shown implemented via crosstalk between CCR5 and NK1R-T on 
monocytes (Chernova et al. 2009).  
 
SP is involved in leucocyte adhesion to endothelial cells and has been 
reported to induce the expression of endothelial-leucocyte adhesion 
molecule-1 on human small vessel endothelium, increase the expression of 
the leucocyte integrin CD11b on human neutrophils, and enhance the 
expression of intercellular adhesion molecule-1 and leucocyte function-
associated antigen-1 on murine endothelial cells and lymphocytes (Matis et 
al. 1990; Vishwanath et al. 1996).   
 
SP influences host responses in both viral and bacterial infections. In 
infections, increased expression of SP and its receptor have been reported 
(Jacoby et al. 2000; Tripp et al. 2000; Kwan et al. 2001). Antagonism of 
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NK1R limits Th1 responses during salmonellosis with decreased IFN-J 
mRNA expression in mucosal tissues (Kincy-Cain et al. 1996), NK1R 
deficient mice show reduced granuloma formation and IFN-J production in 
infection with Schistosoma mansoni (Blum et al. 1998; Blum et al. 1999). 
Increased viral or bacterial burden and accelerated disease progression with 
impaired natural killer activity have been described in several studies with 
impaired SP response (Svensson et al. 2005).  
Vilisaar, J. 
 25 
2.2 Multiple sclerosis 
2.2.1 General features of MS 
MS is an autoimmune disease of the CNS characterised by multifocal 
inflammatory demyelination and neuronal loss. The disease affects 
predominantly younger people with an onset usually in the third or fourth 
decade. Like other autoimmune conditions it is preponderant in females 
with a female/male ratio of 3/2 to 2/1 (Confavreux et al. 1980). The main 
target of inflammation is myelin and myelin-producing oligodendrocytes 
that enclose and insulate axons. The inflammatory breakdown of myelin 
leads to impairment in nerve conduction which results in clinical 
symptoms and signs.  
 
2.2.2 MS clinical presentation 
MS presents with an abrupt onset of neurological symptoms, usually for 
weeks, followed by a complete or partial recovery. Symptoms and signs 
depend on the tracts affected and the location of the lesion. MS manifests 
frequently in the optic nerve and sensory disturbances (numbness, 
paraesthesiae, pain), motor findings (weakness, spasticity) and cerebellar 
features (ataxia, tremor), bladder and bowels dysfunction and commonly 
with generalized fatigue. The diagnosis is based on evidence for at least 
two demyelinating events at different sites, separated in time (for 
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diagnostic criteria please see Appendix B) (Polman et al. 2011). In 80% of 
patients MS presents as a relapsing-remitting (RR) type, which in a 
majority of cases advances into the secondary progressive stage (Compston 
et al. 2002; Compston et al. 2008). Approximately 15 % of patients present 
from the onset with primary progressive MS (PPMS) and about 5% have a 
benign form of MS which does not progress (Compston et al. 2002). 
Pathologically, these clinical types of MS reflect different combinations of 
acute inflammatory and chronic neurodegenerative processes. 
 
2.2.3 Etiological factors in MS 
MS has been considered a polygenic disease, however until date, no major 
susceptibility genes have been identified. Association with the haplotype 
DR2 (Ebers et al. 1995) and coexistence of other alleles of the human 
leucocyte antigen (HLA) class II (Frohman et al. 2005) have been found, 
having implications in antigen presentation. There is also evidence of MS 
being linked to environmental factors, the prevalence of MS increasing 
with latitude (Kurtzke 1980). Associations with several intracellular 
pathogens have been suggested in MS pathogenesis, such as measles, 
rubella, mumps, parainfluenza, HTLV-I, herpes simplex and Epstein-Barr 
viruses, Chlamydia pneumoniae (Wingerchuk et al. 2001). Nevertheless, 
no clear causal relationship between any of these infections and MS has 
been consistently confirmed. Recently, associations of increased risk for 
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the disease have been found with low 1,25-dihydroxyvitamin D3 levels 
and smoking (Ascherio et al.; Smolders et al.; Jafari et al. 2009). 
 
2.2.4 Immunoactivation in MS 
The effect of infectious agents seems important in activating cellular 
immune responses with 10% of infections being followed by a relapse in 
patients with defined MS and 30% of first presentations being related to a 
preceding infection (Compston et al. 2002). The latter can be explained by 
immune system activation via the mechanism of molecular mimicry in 
genetically susceptible individuals. In molecular mimicry immune cells of 
the body become activated towards myelin components that structurally 
resemble foreign antigens. In the course of the disease epitope spreading 
may as well be involved making the inflammatory response more myelin 
specific. The target antigens in MS are not proven; proteolipid protein 
(PLP), myelin basic protein (MBP), myelin-oligodendrocyte glycoprotein 
(MOG) and myelin-associated glycoprotein (MAG) epitopes have been 
suggested based on MS animal models and on indirect evidence on humans 
(Mokhtarian et al. 1984; Satoh et al. 1987; van der Veen et al. 1989; 
Kuchroo et al. 1991; Kerlero de Rosbo et al. 1993). 
 
2.2.5 Cellular immune responses and BBB penetration 
Inflammation in MS is driven mainly by cell mediated immunity. 
Autoreactive T cells against myelin epitopes are present physiologically 
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and believed to be controlled by naturally occurring as well as induced 
subgroup of T cells known as regulatory T cells (Tr). Immunoregulatory 
defects of Tr found in MS are believed to result in activation and 
proliferation of autoreactive T cells (Baecher-Allan et al. 2006). The latter 
attach themselves to the lining of cerebral venules, allowed by 
upregulation of adhesion molecules such as D4-integrin on them and 
induction of VCAM-1 and ICAM-1 (Pober et al. 1986; May et al. 1992; 
Arnason 1996) reciprocally on CNS endothelia (Vajkoczy et al. 2001; 
Frohman et al. 2005). Previously, SP role in ICAM-1, VCAM-1 expression 
(Nessler et al. 2006) and leukocyte-endothelial cell adhesion have been 
shown (Harrison et al. 2001). Release of matrix metalloproteinases enables 
breakdown and penetration of the blood-brain barrier (BBB). Additionally, 
modulatory role of SP in BBB integrity has been proposed (Kostyk et al. 
1989; Cioni et al. 1998). Recently, the role of mast cells, located 
perivascularly, has been implicated in developing autoimmune 
inflammation, whereas SP has been shown an important role as a mediator 
in this function (Theoharides et al. 2008). Several SP effects in mast cells 
have been established, such as inducing degranulation, histamine, 
serotonin and inflammatory cytokine release that contribute to the cascade 
damaging the BBB (O'Connor et al. 2004). Mast cells can stimulate 
activated T cells coming in contact with them at the BBB, e.g. after 
stimulation with myelin basic protein or SP (Theoharides et al. 2008). 
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2.2.6 Inflammatory cascade in the CNS 
In the CNS, autoreactive T cells activate microglia and astrocytes 
(Frohman et al. 2005) that act as local antigen presenting cells (APC) re-
presenting the antigen of myelin to T cells. Activated T cells and APC 
release cytokines that lead to the propagation of inflammation and 
recruitment of other immune cells via secretion of chemokines (RANTES, 
MCPs, MIPs, IL-8). The recruited monocytes, differentiating into 
macrophages, are the main effector cells degrading myelin. They 
phagocytose myelin lamellae with release of different proteolytic enzymes, 
NO, free radicals, H2O2 and cytokines (Traugott et al. 1983). Another 
group, CD8+ T cells (Tc), may have a suppressor function in MS with 
secretion of IL-4, IL-10 and TGF-E, but have also been implicated as 
potentially pathogenic. They are more abundant than CD4+ helper cells 
(Th) in MS lesions (Crawford et al. 2004). The immune pathways 
involving Th subsets Th17, Th1, and Th2 determine the balance of the 
inflammatory arms and mediate autoimmune damage to myelin. 
Neuropeptides, including SP, have been shown to modulate Th phenotype 
commitment (Levite 1998). 
 
2.2.7 Role of humoral responses 
B cells and plasma cells are also activated in MS and have been found in 
and near MS lesions (Arnason 1996). IL-4, released by Th2 cells, has the 
main role in facilitating humoral responses (Arnason 1996). Oligoclonal 
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IgG is present in plaques and found as oligoclonal bands (OCB) in 
cerebrospinal fluid (CSF) electrophoresis in more than 90% of MS patients, 
indicating local oligoclonal activation. Activation of complement in active 
lesions has been demonstrated (Compston et al. 1989; Storch et al. 1998) 
which by causing opsonisisation of myelin antigens stimulates and focuses 
the autoimmune attack (Mosley et al. 1996). 
 
2.2.8 Propagation of lesions and direct neuronal injury 
The above phenomena result in lesions of both white and grey matter. In 
the brain, they frequently show periventricular distribution. Lesions start as 
perivenous infiltration of lymphocytes, activated macrophages and 
microglia, followed by proliferation of astrocytes that prevail at later stages 
leading to gliosis. Oligodendrocyte and myelin damage by macrophages 
exposes neurons impairing their conduction and enabling direct injury. 
Effector cells and released cytokines, proteinases, free radicals, NO as well 
as glutamate can all contribute to neuronal injury. It is plausible that on 
neuronal injury, SP may be released, which in turn is involved in 
stimulating and maintenance of inflammation. Interstitial oedema is 
evident in acute stages with a possible neurogenic role of SP (Brenner et al. 
1994). Heterogeneity in pathogenic mechanisms of MS has been observed 
and distinction of four major pathological patterns has been suggested 
(Lucchinetti et al. 2000) 
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2.2.9 Neurodegenerative features of MS 
Pathological evidence and magnetic resonance imaging (MRI) have shown 
that neurodegeneration with damage to axons and neuronal cell bodies is 
present from the earliest stages of the disease (Ferguson et al. 1997; Trapp 
et al. 1998; Bitsch et al. 2000; Kornek et al. 2000; Kuhlmann et al. 2002). 
This is accompanied by reparative processes and remyelination 
commencing in the acute inflammatory phase. Activated T cells, 
monocytes, astrocytes and microglia produce various neurotrophic factors, 
such as brain-derived neurotrophic factor (BDNF), activity-dependent 
neuroprotective factor (ADNF) (Braitch et al.; Kerschensteiner et al. 1999; 
Kerschensteiner et al. 2003) that support neuronal survival, regeneration, 
synaptogenesis as well as remyelination (Coyle 2005). There is also 
evidence of SP involvement in neuronal survival as part of the protective 
arm of inflammation (Barker 1986; Salthun-Lassalle et al. 2005; Amadoro 
et al. 2007). 
 
2.2.10 MS animal models targeting SP role 
In vivo evidence on SP role in CNS demyelination comes from studies on 
EAE mice using NK1R antagonists or NK1R knockout model. NK1R 
antagonist CP-96345 administered before the disease onset has been shown 
to considerably ameliorate the clinical and histological signs in T cell 
transfer EAE (Nessler et al. 2006). The protective effect of CP-96345 was 
attributed to a reduced expression of adhesion molecules ICAM-1 and 
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VCAM-1 on CNS endothelia (Nessler et al. 2006) and reduced secretion of 
pro-inflammatory (Th1) cytokines in treated animals (Nessler et al. 2006). 
Milder clinical presentation has been shown in NK1R deficient mice with 
also decreased numbers of LFA-1 high CD4+ T cells and MOG-specific, 
IFN-Ȗ producing CD4+ cells (Reinke et al. 2006). NK1R antagonist 
SR140333 administered during the chronic phase of EAE has proved 
insufficient ameliorating EAE symptoms (Reinke et al. 2006). In humans 
suggestions on SP involvement in MS come from linkage studies that have 
highlighted TAC1 association with MS (Vandenbroeck et al. 2002; 
Cunningham et al. 2005). 
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2.3 Aims 
The primary aims of the study are as follows: 
1. To determine the role of NK1R mediated effects on the 
expression of various inflammatory cytokines, such as IL-23, 
IL-12 IL-ȕ ,/-6, IL-8, IL- 71)Į LQ 3%0& IURP QRUPDO
controls. 
2. To investigate the expression of SP and its receptor in T cells in 
a normal state and on stimulation with the main Th17 and Th1 
cytokines, i.e. IL-23, IL-17, IL-12, IFN-J. 
3. To study the possible intermediary roles of IL-17 and IFN-Ȗ in 
the IL-23 and IL-12 effects respectively in the induction of SP 
and NK1R in T cells from healthy controls. 
4. To investigate the expression of SP and its receptor in human 
NT2 neurons as an effect of IL-17, as part of the Th17 response, 
in comparison with IFN-ȖDVSDUWRIWKH7KSDWKZD\ 
5. To determine NK1R expression in peripheral blood cells in an 
unstimulated state comparatively in RRMS patients and healthy 
volunteers. 
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3 The induction of inflammatory cytokines by substance P in 
human peripheral blood mononuclear cells 
3.1 Introduction 
The induction of inflammatory cytokines is one of the main mechanisms 
by which SP exerts its immunomodulatory effects. In this chapter we have 
studied SP-induced inflammatory cytokine expression on both protein and 
mRNA-level. The cells used for this purpose are peripheral blood 
mononuclear cells (PBMC) that refer collectively to a population of 
monocytes, lymphocytes and antigen-presenting cells. PBMC cultures 
represent a good experimental setup for studying this regulation as these 
cells represent the main source of inflammatory cytokines in the 
circulation. Additionally, immune interactions between these cells in vivo 
are important determining the type of immune responses.  
 
In the context of MS the inflammatory pathways associated with the 
created cytokine profiles can be characterized by means of three main 
subtypes of Th responses: Th1, Th2 and Th17. The main role responsible 
for inflammatory activity in MS is currently attributed to the recently 
uncovered Th17 cells (Harrington et al. 2005; Hofstetter et al. 2005; 
Komiyama et al. 2006). The effects and co-effects of cytokines secreted 
and engagement of the inflammatory pathways governs further 
differentiation of the cells and determines the balance of the inflammatory 
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arms. The three subtypes of Th responses are known to antagonise each 
other on a cytokine and likely also on a transcription factor level (Korn et 
al. 2007). This reflects their interdependency of each other and enables to 
maintain the created immunological profile. 
 
It has been shown that Th17 cells with strong pro-inflammatory effects are 
differentiated mainly by the co-effect of TGF-ȕ and IL-6 and at the later 
stage maintained by IL-23 via signal transducer and activator of 
transcription (STAT)3 and the orphan nuclear receptor RORgammat 
(Ivanov et al. 2006). Th1 population with mainly pro-inflammatory 
features is driven by IL-12 and IFN-Ȗ via STAT1, STAT4 and T-box 
transcription factor T-bet. Th2 cells with anti-inflammatory effects are 
induced by IL-4 via STAT6 and subsequently by the zinc-finger 
transcription factor GATA3 (Murphy et al. 2002) (Fig 3.1). It has been 
shown that neuropeptides, such as SP, can modulate Th phenotype 
commitment (Levite 1998).  
 
Th1 cells are known to activate macrophages and other immune cells via 
secretion of pro-inflammatory cytokines including IFN-J, TNF-E, IL-1, IL-
2 (Roitt et al. 2001), however recently it has been found they may also 
exhibit autoimmune inflammation limiting effects (Iwakura et al. 2006; 
McKenzie et al. 2006). The effects of Th2 cells, in MS context, via 
secretion of IL-4, IL-5, IL-10, IL-13, IL-25, include mainly downgrading 
activity of immune cells (i.e. cell-mediated immunity), as well as antibody 
Vilisaar, J. 
 36 
generating function. Th17 effects include secretion of IL-17A, IL-17F, IL-
21, IL-22 and to a lesser extent TNF and IL-6 (Bettelli et al. 2007). 
Depending on the stimulatory effects, populations of PBMC produce a 
combination of inflammatory cytokines. 
 
 
 
Figure 3.1.  Differentiation and characteristics of CD4+ cells representing 
three main effector phenotypes (A - inhibitory effects, p - stimulatory effects) 
(Korn et al 2007). 
 
Different co-effects and so called chain effects exist in induction of the 
studied cytokines. For example IL-12, secreted largely by APC, such as 
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macrophages, dendritic cells, and in the CNS also by microglia (Gran et al. 
2004), is known to exert its effects either directly or via inducing 
production of IFN-J. IFN-J, secreted predominantly by Th1 cells, has 
potent pro-inflammatory effects. Similarily IL-23, a relatively newly 
discovered pro-inflammatory cytokine sharing the same p40 subunit, E1 
receptor chain and some of the signalling steps as IL-12 (Hoeve et al. 
2006), can exert its effects directly or via promoting IL-17 production by 
Th17 cells (Aggarwal et al. 2003). IL-17 has various actions, including 
induction of IL-ȕ 71) ,/-6, several chemokines, colony-stimulating 
factors, matrix metalloproteinases from a series of different cell types 
(Kolls et al. 2004). 
 
There has been a lot of discussion about the kinetics and interaction of the 
two pro-inflammatory pathways in the pathogenesis of MS. The 
importance of IL-23 versus IL-12 role in autoimmune demyelination has 
been extensively studied in vivo. In EAE model IL-23 but not IL-12 
requirement in autopathogenic T cell response implicates the central role 
for IL-23/IL-17 axis. Both IL-23 and IL-17 knockout and therapeutic 
neutralisation experiments in EAE have supported resistancy to EAE or 
amelioration of the disease course (Hofstetter et al. 2005; Langrish et al. 
2005; Chen et al. 2006; Komiyama et al. 2006). However, it seems Th17 
responses may have a role earlier compared to Th1 cells which may be 
recruited by Th17 effects and have a role at later stages of inflammation.  
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SP effects on autoimmune inflammation and cytokine induction relevant to 
this chapter have been explained above (please see section 2.1.12). As a 
result from previous studies, SP has been found to induce activation of the 
pro-inflammatory pathways. Using PBMC cultures we will elucidate the 
net effects of SP, objectivised in our case by the expression of the 
inflammatory cytokines, such as IL-12, IL-23, IL-1, IL-6, IL-10, IL-8, 
71)ĮIn particular we have been focussing on IL-12 and IL-23 induction 
as the key cytokines in Th1 and Th17 pathways respectively. 
 
As an acknowledgement for work contributing to this chapter, a portion of 
ELISA and qPCR experiments were done by Dr K Kawabe and Ms M 
Braitch. 
3.2 Methods 
3.2.1 Cell preparations and cultures 
PBMC were isolated by standard gradient centrifugation. Blood was 
obtained on venepuncture from healthy volunteers. 10 ml of whole blood 
was diluted with an equal volume of RPMI 1640 medium (Sigma-Aldrich, 
UK) with 6 ml of Histopaque 1077 (Sigma-Aldrich, UK) layered 
underneath blood and media. The solution was centrifuged for 20 minutes 
at 715 u g. PBMC were isolated at the interface between the medium and 
the Histopaque. Harvested cells were washed twice, first with 20 ml of 2 % 
Fetal Calf Serum (FCS, Sigma-Aldrich, UK) in RPMI (consisting of 2 mM 
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Glutamine, 20 mM Hepes, 0.1 mg/ml Penicillin and Streptomycin) and 
centrifuged at 715 u g for 15 minutes, and subsequently with 10ml of 2 % 
FCS in RPMI and centrifuged at 400 u g for 10 minutes. Cells were 
resuspended in 5ml of 10% FCS in RPMI and aliquotted in 1:1 dilution 
with 0.4% Trypan blue (Sigma-Aldrich, UK) for cell counting and viability 
check. Cells were counted using a haemacytometer (Marinfeld Laboratory 
Glassware, Germany). PBMC were diluted with 10% FCS in RPMI to the 
concentration of 106 cells/ml, plated on 24 well plates 1ml/well and 
stimulated.  
3.2.2 Stimulation of cell cultures 
PBMC at a concentration 106/ml were stimulated for 24 h and 48 h with 
10-6 - 10-12 M SP (Sigma-Aldrich, UK) with and without the presence of 
following agents: NK1R antagonist CP-96345 (Pfizer, UK) 10-3 M -10-6 M; 
an inactive enantiomer of the latter CP-96344 (Pfizer, UK) 10-3 M -10-6 M; 
anti-NK1R antibody (Chemicon International Inc) 1:500 or 1:1000; 
lipopolysaccharide (LPS, E. coli serotype 0111:B4, Sigma-Aldrich, UK) 1 
ȝJPO$IWHU FHOO FXOWXUH VWLPXODWLRQV WKH VXSHUQDWDQWVZHUH UHPRYHGDQG
stored at -& 
For stimulations SP as an acetate salt hydrate (SigmaAldrich, UK) was 
dissolved in distilled water and stored at ±20 qC (see also section 2.1.2), 
CP-96345 and CP-96344 were dissolved in distilled water. 
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3.2.3 Flow cytometric bead array for IL-1ȕ, IL-6, IL-8, IL-10, IL-12p70, 
TNF-Į 
For Cytometric Bead Array (CBA) on Fluorescence-Activated Cell Sorting 
(FACS) commercial CBA Inflammatory Kits (BD Biosciences Pharmingen, 
86$ ZHUH XVHG DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V &XOWXUH 6XSHUQDWDQW
Assay procedure. The following two modifications to the procedure were 
made: 
1. One extra standard for higher and smaller concentrations were 
added, 10,000 pg/ml and 10 pg/ml respectively; 
2. Samples were incubated with capture beads as two separate 
subsamples. The first subsample of 5/6 of the total sample volume 
was incubated with the mixture of IL-ȕ ,/-6, IL-10, IL-12p70, 
TNF-ĮEHDGVDQGWKHVHFRQGVXEVDPSOHGLOXWHGGXHWRKLJK
concentrations of IL-8) and of 1/6 total sample volume accordingly 
with IL-8 beads. After washing, the subsamples were added and 
treated per protocol.  
For analysis EPICS Altra flow cytometer (Beckman Coulter) and WinMDI 
2.9 software were used. 
3.2.4 ELISA for IL-12 and IL-23 subunits on PBMC culture supernatants 
Concentrations of different IL-12 and IL-23 subunits in stimulated PBMC 
culture supernatants were measured using commercial ELISA (Enzyme-
Linked Immunosorbent Assay) kits. IL-12p40 (Diaclone, USA), IL-12p70 
(eBioscience, USA) and IL-23 p19/p40 (eBioscience, USA) kits were used 
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IROORZLQJ WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV 7KH DVVD\ Vensitivities were 
specified as follows: below 20 pg/ml for IL-12p40, below 15 pg/ml for IL-
23 p19/p40 and 4 pg/ml for IL-12p70. 
3.2.5 Total RNA extraction from stimulated cells 
This step was carried out by column extraction method using commercial 
51HDV\ NLW 4LDJHQ *PE+ *HUPDQ\ DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V
protocol. The homogenization step was performed using needle 
homogenisation method. Total RNA concentration was measured using 
1DQR'URS1'-1000 spectrophotometer (NanoDrop Technologies, USA). 
Purity was assessed by measuring 260/280 nm ratio, only samples within  
the range 1.70-1.95 were used. 
3.2.6 Reverse transcription 
First strand cDNA synthesis was initiated from the same amount of total 
RNA in each sample using random hexamers. To denature the secondary 
structure and anneal oligonucleotide primers to the RNA 0.3-J WRWDO
51$ ZDV LQFXEDWHG ZLWK  O RI UDQGRP SULPHUV 3URPHJD 86$ 
JO LQ D ILQDO YROXPH RI  O PDGH XS ZLWK QXFOHDVH-free water 
(Sigma-$OGULFK 8. DW  & IRU  PLQXWHV 8QWLO the next step the 
microcentrifuge tubes with the above mixture were kept on ice. The 
IROORZLQJFRPSRQHQWVRIWKHWRWDOYROXPHRIOZHUHDGGHGWRHDFKWXEH
ȝO[00/90RORQH\0XULQH/HXNHPLD9LUXV5HYHUVH7UDQVFULSWDVH
Buffer (Promega, USA), 1.25 ȝO G173V P0 G$73 G&73 G*73
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G8733URPHJD86$ȝORI5LERQXFOHDVH,QKLELWRU3URPHJD86$
ȝO00/95HYHUVH7UDQVFULSWDVH3URPHJD86$DQGȝOQXFOHDVH-
free water (Sigma-Aldrich). The reverse transcription was carried out by 
incubating the mixture at 42 qC for 1 hour. The resultant cDNA was 
GLOXWHGZLWKORIQXFOHDVH-free water for real-time PCR or stored at ±20 
qC. 
3.2.7 Quantitation of IL-23p19, IL-12p40 and IL-12p35 transcripts 
 
Quantification of transcripts was carried out using real-time PCR and the 
relative standard curve method as described by Applied Biosystems 
(AppliedBiosystems 1997). For the set of standards equal aliquots of 
undiluted cDNA from each sample were pooled together and serially 
diluted 1:2, 1:5, 1:10, 1:20. For each sample 12.5 Pl of SYBRGreen 
Mastermix (Stratagene, USA), 6 Pl nuclease-free water (Sigma-Aldrich, 
UK), 0.75 Pl forward and 0.75 Pl of reverse primers (10 pmol/Pl) were 
mixed with 5 Pl target cDNA/standard/water per tube. The real-time PCR 
reactions were carried out in triplicates on multiplex qPCR system 
Mx4000 (Stratagene, USA). The following conditions were used: 10 
mins at 95 qC to denature the secondary structure followed by 40 cycles of 
alternating 95 qC for 15 sec and 54-62 qC (depending on Tm of primers) 
for 1 min. For dissociation curves the additional incubation at 95 qC for 1 
minute and subsequent 40 cycles each with 1 qC increment in temperature 
IURPWR&HYHU\VHFRQGVZHUHDGGHG'LVVRFLDWLRQFXUYHVZHUH
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used routinely for each reaction to assess product homogeneity. The 
following primer sequences were used for IL-23p19 sense: 
¶FWFFFWJDWDJFFFWJWJ¶ DQWLVHQVH ¶JDFWJDJJFWWJJDDWFW¶ IRU ,/-12p40 
VHQVH¶JJDJWDFFFWJDFDFFWJ¶ DQWLVHQVH¶DJDWJDFFJWJJFWJDJJ¶ IRU ,/-
SVHQVH¶FFDFWFFDJDFFFDJJDDWJ¶DQWLVHQVH¶JDFJJFFFWFDJFDJJW¶
(Lee et al. 2004))RUVWDQGDUGLVDWLRQȕ-PLFURJOREXOLQȕ0*JHQHZDV
used as an internal standard relative to which the ratios of the reaction 
SURGXFWVZHUHWDNHQ7KHSULPHUVXVHGIRUȕ0*ZHUHDVIROORZVVHQVH
¶FWFFJWJJFFWWDJFWJWJ¶ DQWLVHQVH ¶WJJDWJDDDFFFDJDFDFDWDJ¶ 7KH
reaction efficiency was optimal with template in 1:5 dilution and primer 
FRQFHQWUDWLRQVSPROOIRUDOORIWKHDERYHUHDFWLRQV7KHSURGXFWVL]H
was confirmed on agarose gel electrophoresis. Further information about 
data analysis of the qPCR step is provided in Appendix A. 
3.2.8 Agarose gel electrophoresis on the amplification product 
Agarose gel electrophoresis was used to optimise conditions for reactions 
to all three subunits as well as for confirmation of the product size. 1.6 % 
agarose gel (Bioline, UK) was prepared in 1xTBE buffer (Tris, Boric acid, 
EDTA). 5 Pl PCR product with 1 Pl 1oading buffer and a 100 bp DNA 
ladder (Sigma-Aldrich, UK) were run at 100 V for 50-60 min. The gel was 
VWDLQHG ZLWK HWKLGLXP EURPLGH  J PO IRr 25 minutes and 
visualised under the UV-light (260 nm). 
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3.2.9 Statistical analysis 
For statistical analysis Friedman and Wilcoxon tests were used in SPSS 
16.0 software. Non-parametric tests are used for analysis throughout the 
thesis due to non-Gaussian distribution of the results. 
 
3.3 Results 
3.3.1 CBA for IL-12, IL-1ȕ, IL-6, IL-8, IL-10 and TNFĮ protein level 
induction by SP 
SP-induced production of the above inflammatory cytokines by PBMC 
was measured on PBMC culture supernatants. CBA did not show 
significant stimulatory effects of SP in these assays neither at 24h nor 48h. 
There was a trend for IL-8 and IL-6 induction in some individual samples 
on stimulation with SP 10-6 M and 10-12 M in a concentration-dependent 
fashion which was more pronounced at 24 hours than after 48 hours. SP 
showed additive effects on co-stimulation with LPS on IL-8 and IL-6 
production (Fig 3.2), however, statistically these were not significant.  
 
No induction of IL-12 in response to SP was detected. LPS 1 Pg/ml neither 
in this IL-12 assay showed stimulatory effects on IL-12 production. 
Interestingly, CP-96345 at concentrations 10-4 M or higher showed 
inhibitory effects on LPS-stimulated and SP and LPS co-stimulated cells  
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Figure 3.2. CBA-detected inflammatory cytokine concentrations (pg/ml) in 
cell culture supernatants of PBMC stimulated with SP 10-6 M and/or LPS 1 
ȝJPO5HVXOWVUHSUHVHQWPHDQVRIH[SHULPHQWVIURPGLIIHUHQWVXEMHFWV- 
SEM. 
Stimulation conditions 
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on IL-1E, TNF-D, IL-6, IL-8 and IL-10 production which will be discussed 
below (data not shown). 
 
3.3.2 Flow cytometry on PBMC stimulated with LPS and CP-96345/CP-
96344 
The above described finding with CP-96345 reducing the effect of LPS 
was further investigated with different concentrations of CP-96345, its 
inactive isomer CP-96344 and antibodies to NK1R at two different 
concentrations 1:500 and 1:1000. The effect of CP-96345 was dose-
dependent and marked with the highest concentration of 10-3 M (Fig 3.3). 
Similar effects were seen with CP-96344 but not with NK1R antibody. 
This showed that the effect was not mediated via NK1R binding, however, 
interaction of SP with CD14/TLR4/MD2 complex, that the results led to 
hypothesize, could not be ruled out. The cells incubated with CP-96345 for 
24 hours at concentrations 10-6, 10-5, 10-4, 10-3 M and stained with 
propidium iodide (of final concentration 0.5 Pg/ml) showed an increasing 
population of dead cells on flow cytometry from a concentration 10-4 M 
upwards suggesting toxicity of CP-96345 and CP-96344 at higher 
concentrations. In the following experiments CP-96345 and CP-96344 
concentrations of 10-6 M were used. 
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Figure 3.3. Flow cytometry histograms on propidium iodide staining of 
PBMC after exposure to different concentrations of CP-96345 (10-6 M, 10-5 M, 
10-4 M, 10-3 M). The results represent a single experiment with cells isolated 
from one control subject. 
CP-96345 10-3 M 
CP-96345 10-4 M 
CP-96345 10-5 M 
CP-96345 10-6 M 
Control 
Vilisaar, J. 
 48 
 
3.3.3 ELISA for protein level induction of IL-12 and IL-23 by SP 
Three different subunit ELISAs were used to study IL-12 and IL-23 
expression in PBMC. IL-12/23p40 ELISA on PBMC culture supernatants 
showed no significant induction of p40 by SP at 10-6 M or 10-12 M neither 
at 24 h nor 48h (Fig 3.4). 
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Figure 3.4. A representative example of one IL-12p40 ELISA on tissue 
culture supernatants of PBMC stimulated with SP with two different 
concentrations 10-6 M and 10-12 M for 24h and 48h. Similar results were 
obtained in 2 additional assays. 
 
Relying on the sensitivity of ELISA compared to other methods we have 
tested different concentrations of SP including 10-6, 10-8, 10-10, 10-12 M 
using IL-12p40 assay. A small concentration-dependent effect was 
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observed with SP 10-6 M giving the best response, additionally some dose-
dependent additive effects were seen in some sets on co-stimulation with 
SP and LPS. The experiments were repeated using three different IL-12p40 
kits. The only significant results were seen on stimulation with LPS 1 
JPODQGRQFR-VWLPXODWLRQZLWK/36JPODQG63DW-6 M and 10-12 
M. The differences between SP 10-6 M and 10-12 M were not significant, 
nor was significant the additional effect of SP added to LPS as compared 
to LPS only.  
 
On IL-12p70 and IL-23p19/p40 assays SP failed to upregulate p70 and p40 
both at 24h and 48h (see Fig 3.5 and Fig 3.6). The only positive result was 
again seen on stimulation with LPS. LPS-induced expression of IL-12p70 
was inhibited by both CP-96345 10-6 M and CP-96344 10-6 M, whereas SP 
antagonist and pseudo-antagonist had no effect on LPS upregulation of IL-
23p19/p40. The effects for IL-23 induction by LPS were clearly more 
pronounced at 24h compared to 48h, this difference between 24h and 48h 
was not evident for IL-12. 
 
Pre-stimulation experiments with LPS were additionally tested in which 
isolated PBMC were pre-stimulaWHGZLWK/36ȝJPODQGLQFXEDWHGIRU
24 h at 37 qC, 5% CO2 alongside with non-LPS-pretreated cells, and 
subsequently stimulated with the usual conditions as above. The 
experiment was repeated twice on PBMC from two different subjects. 
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Neither IL-12p70 nor IL-23p19/p40 ELISA showed significant differences 
from LPS pre-treatment. 
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Figure 3.5. IL-12p70 concentrations in PBMC culture supernatants as 
detected by ELISA comparatively after 24 h and 48 h stimulation. 
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Figure 3.6. ELISA results on IL-23p19/p40 concentrations in PBMC culture 
supernatants after 24 h and 48 h stimulation. 
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3.3.4 mRNA-level expression of IL-12 and IL-23 subunits in PBMC on 
stimulation with SP 
These experiments with a 24-hour induction with SP were done on PBMC 
from 5 healthy volunteers. The expression of the three IL-12 and IL-23 
subunits showed a similar response to stimulation with SP and suppression 
by CP-96345, but not by CP-96344. SP strongly upregulated the 
expression of the subunits in a similar degree to LPS (Figs 3.7, 3.8, 3.9).  
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Figure 3.7. IL-12p35 mRNA abundance in PBMCs in response to a 24h 
incubation with different stimuli. The values represent arbitrary units after 
QRUPDOLVDWLRQZLWKȕ0*DVDQLQWHUQDOVWDQGDUG7KHUHVXOWVDUHEDVHGRQ
different controls, error bars represent SEM. 
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Figure 3.8. IL-12/23p40 mRNA abundance in PBMCs stimulated for 24 h, 
QRUPDOLVHGZLWKȕ0*7KHYDOXHVUHSUHVHQWDYHUDJHVRIGLIIHUHQWFRQWUROV
+/- SEM. 
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Figure 3.9. IL-23p19 mRNA abundance in PBMCs after 24h stimulation, 
QRUPDOLVHG ZLWK ȕ0* 5HVXOWV DUH SUHVHQWHG DV DYHUDJHV RI  GLIIHUHQW
controls +/- SEM. 
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The induction of the p40 subunit by SP was the greatest with a 6.2-fold 
increase (p=0.043), followed by p19 and p35 induction with a 2.7-fold 
(p=0.068) and 2.3-fold (p=0.043) increase in the level of their expression 
respectively.  
The previously observed phenomenon of CP-96345 and CP-96344 
blocking LPS effects were showing a similar trend in these experiments 
only with CP-96345, particularly in IL-12p35 and IL-23p19 series. 
The product homogeneity and size for each of the conditions were 
confirmed on agarose gel electrophoresis with a product size of 131 bp for 
IL-12/23p40, 62 bp for IL-12p35, 109 bp for IL-23p19, and 148 bp for 
ȕ0* 
3.4 Discussion 
The protein-level expression of the inflammatory cytokines on CBA did 
not show significant induction by SP. Additionally, IL-12 could not be 
induced with LPS using IL-12 p70 beads suggesting low sensitivity of the 
assay. Other cytokine bead assay sensitivities were sufficient as assessed 
by the positive control stimulus. Our results in CBA set apart trends in 
induction of IL-6 and IL-8 as a concentration-dependent response to SP. 
Additionally, additive effects in IL-6 and IL-8 induction were observed on 
co-stimulation with SP and LPS. This may support the presence of some 
effect of SP in the assay. Adding CP-96345 at a concentration 10-4 M or 
higher to SP and LPS stimulated samples significantly reduced the 
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stimulatory effects for IL-1E, TNF-D, IL-6, IL-8 and IL-10 production. The 
latter aspect of CP-96345 findings will be further discussed below. 
 
The comparison of previously published studies reveals contradictory 
results on the above effects of SP. For example, Lotz has shown production 
of IL-1, TNF-Į,/-6 from human blood monocytes by SP (Lotz et al. 1988) 
which is contradicted by Derocq not confirming the ability of SP to induce 
IL-ȕ,/-6, IL-8, TNF-ĮLQKXPDQ3%0&(Derocq et al. 1996), and Lieb 
who also failed to demonstrate IL-1 and IL-6 induction in human 
monocytes (Lieb et al. 1996). Synergistic effects, however, were reported 
on stimulation with LPS and SP on IL-6 production (Lieb et al. 1996) as 
were also observed in our experiments. A great variability of IL-1 response 
to SP in human monocytes has been previously reported (Laurenzi et al. 
1990). Wide contradictions in these studies may indicate that preferentially 
activated cells may respond to SP (Laurenzi et al. 1990). However, the 
comparison of results in these cases is difficult due to the variety of 
commercial assays used in the studies. 
 
NK1R specific antagonist CP-96345 was used to study NK1R mediated 
effects. Previously published CP-96345 concentrations 10-3 M (Wang et al. 
2004) and 10-4 M (Kincy-Cain et al. 1997) have shown clearly toxic dose-
dependent effects in our study. Similar effects were seen with its inactive 
isomer CP-96344 at the same concentrations. Although CP-96345 10-5 M 
appeared not toxic to the cells, caution is needed in drawing conclusions 
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also at lower concentrations. Based on the above findings we have used 
CP-96345 and CP-96344 concentrations of 10-6 M for further experiments 
with still some reduction in LPS effects that is not necessarily due to 
toxicity. This is supported by the fact that CP-96345 at 10-6 M was not 
producing more dead cells than a negative control on propidium iodide 
staining.  Interaction of CP-96345 and CP-96344 with LPS on receptor 
binding level cannot be excluded. Structural analysis for possible binding 
interactions is extraneous to the aims of the study and this was not further 
investigated.  
 
IL-12 and IL-23 protein-level expression was studied further with different 
ELISAs detecting IL-12 and IL-23 subunits. In these assays both IL-12 and 
IL-23 concentrations were indeed low despite a strong positive control. On 
the p40 ELISA neither SP at 10-6 M nor 10-12 M was effective at 24 h and 
48 h. Only LPS and co-stimulation with LPS and SP mounted an induction. 
Higher concentrations of SP were not included due to these not being 
physiological. In subsequent IL-12p70 and IL-23p19/p40 assays SP 10-6 M 
failed to upregulate p70 and p19/p40 both at 24 h and 48 h. The positive 
result was seen only on stimulation with LPS, whereas SP and LPS co-
stimulation in these assays was not included. The effect for IL-23 induction 
by LPS being greater at 24 h than at 48 h is suggestive for IL-23 role 
earlier than that of IL-12.  
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On ELISAs reductions in p40 production were noticeable when adding CP-
96345 at concentrations 10-6 M to the cultures stimulated with LPS and 
both SP and LPS. This phenomenon, as explained above, cannot be 
attributed to CP-96345 toxicity. Both CP-96345 and CP-96344 at 10-6 M 
inhibited the LPS-induced expression of IL-12p70, whereas they had no 
effect on LPS upregulation of IL-23p19/p40. This may suggest that CP-
96345 and CP-96344 interactions with LPS may not necessarily be due to 
receptor binding as this finding distinguishes p70 and p19/p40 differences 
at some point downstream of the receptor level. To test additionally the 
possible role of receptor level interactions pre-stimulation experiments 
with LPS were included. Here neither IL-12p70 nor IL-23p19/p40 ELISA 
showed significant differences from LPS non-pre-treated cells hence not 
fully supporting the idea of CP-96345 interaction with the 
CD14/TLR4/MD2 complex or LPS itself. 
 
Subsequently, mRNA-level expression of the individual subunits was 
studied in which clear induction of all subunits was detectable. The highest 
values were seen with p40 which is consistent with the role of p40 as part 
of IL-12 and IL-23. The common p40 is also found in free form and known 
to yield homodimers in the mouse immune system. The mRNA abundance 
of both IL-12p35 and IL-23p19 was lower but comparable with slightly 
higher levels of p19. This induction could not be shown on the protein 
level, nevertheless, the results suggest that the molecular mechanisms for 
induction of IL-12 and IL-23 by SP are present. This likely involves 
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distinct signalling pathways for IL-12 and IL-23, as also described in the 
literature review (Goodridge et al. 2003). There may be other factors 
downstream regulating the expression of the subunits on a translational 
level and in post-translational processing for p35 (Murphy et al. 2000). 
Alternatively, assay-related problems remain, although less likely, a 
possibility explaining no or little expression of the subunits on the protein 
level. 
 
From the literature IL-12 induction by SP has been previously shown in a 
single mRNA level study on murine macrophages (Kincy-Cain et al. 1997). 
In the study SP agonist concentrations with which the effects could be 
elicited were as low as 10-9 M. We have used concentrations as high as 10-6 
M in our series. In the above study both IL-12p40 and IL-12p35 mRNA 
was potently induced, IL-12p70 expression was not increased. On the 
protein level at 24h IL-12p40 was induced, however no detectable 
secretion of p70 occurred (Kincy-Cain et al. 1997). We have not tested p70 
in our series. Additive effects of SP on LPS in IL-12 induction were 
observed as were also seen in our experiments on PBMC. No studies, 
except this one, have been published showing IL-12 protein-level induction 
by SP. Moreover, studies on IL-23 induction by SP have not been 
published and in humans neither IL-12 nor IL-23 induction has been 
previously shown.  
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Monocytes, which are part of the PBMC population, have been recently 
reported to express NK1R-T (Chernova et al. 2009). The latter may require 
co-stimulation, such as has been shown for NK1R-T and CCR-5 
(Chernova et al. 2009). This crosstalk of receptors is likely needed to elicit 
signalling events. To better characterize SP effects on various cell types, 
the receptor isoforms would need determining in cell populations. 
Additionally, for SP to mount a pro-inflammatory response, the 
requirement of co-stimulation with other mediators, such as RANTES, 
need to be elucidated. This aspect may also explain some inconsistencies 
and poor protein level results as co-signalling may be required for 
downstream events. It is possible that the expression of different receptor 
isoforms and the presence of other mediators may dictate the response of 
SP in a particular inflammatory setting. 
 
With regards to the previously observed peculiar effects of CP-96345 and 
CP-96344, the LPS stimulation of all subunits showed inhibition on the 
mRNA-level only with CP-96345. This was done at a concentration 10-6 M 
for both CP-96345 and CP-96344 as our experiments initially suggested. 
On the contrary, CP-96344 was behaving similarly to SP showing 
synergistic effects with LPS on the mRNA-level. Additionally CP-96344, 
when co-stimulated with SP, gave consistent additive effects suggesting 
agonistic features of CP-96344. Despite strong trends the effects with SP 
antagonist and pseudo-antagonist did not reach the significance level 
mainly due to low numbers of the experiments in which the conditions 
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were additionally added. If these findings are true, however, they show an 
interesting pattern that may require further studies with larger number of 
experiments to allow more definite conclusions.  
 
The results represent net cytokine responses on all subpopulations of 
PBMC. As both IL-12 and IL-23 were induced by SP on the mRNA level 
it can be concluded that both Th17 and Th1 responses are inducible with 
slightly more preponderance to Th17 responses. This supports SP effects in 
pro-inflammatory arm of autoimmune inflammation. As we used a cell 
culture model comprising many different cell types, several effects can 
interact and interfere with the net response, constituting the main limitation 
of the experiments in this chapter. On the mRNA level there are generally 
less factors influencing the expression of the subunits and the results can 
be considered more targeted compared to the protein-level expression 
where also post-transcriptional and post-transcriptional regulation 
influence the outcome. However, at present it is difficult to stipulate 
exactly why the responses on the protein-level were low as measured by 
the cytokine concentrations. 
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4 IL-12 and IL-23 differential effects on substance P and its 
receptor expression in human T cells 
4.1 Introduction 
In the previous chapter we looked at the effects of SP on induction of 
inflammatory cytokines in PBMC. In this chapter we have studied the 
opposite regulation - whether SP and its receptor expression is dependent 
on inflammatory stimuli in T cells as important regulatory and effector 
units in autoimmune inflammation. We have been focussing on the effects 
of main Th1 and Th17 cytokines, in particular the effects of IL-12 and IL-
23. 
 
T cells play a central role in autoimmune disorders characterized by 
delayed type hypersensitivity. They display CD3, a number of subclasses 
are further distinguished, such as CD4+ T helper cells (Th), CD8+ T 
cytotoxic cells (Tc), CD4+CD25+ T regulatory cells (Tr). Other markers 
exist that distinguish and characterize groups more specifically. Th are 
subclassified by the secreted cytokine profiles when activated into a 
particular lineage. Th1, Th2, Th17 represent the main subpopulations of Th 
cells responsible for different types of immune functions (Bettelli et al. 
2007). In our experimental setup we have also employed Jurkat cells that 
are human lymphoblast-like cell line derived from an acute T-
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lymphoblastic leukaemia (Schneider et al. 1977). Jurkat cells are 
effectively used for transfection experiments and studying T cell activation. 
 
IL-12 and IL-23 have some overlapping and some distinct functions. Both 
are capable of inducing proliferation and IFN-ȖSURGXFWLRQE\7FHOOVEXW
whereas IL- SUHIHUHQWLDOO\ DFWV RQ QDwYH 7 FHOOV ,/-23 is involved in 
activation and maintenance of memory T cells (Hoeve et al. 2006). 
Additional distinctions exist such as their autocrine effects on dendritic 
cells. IL-23 is known to specifically induce the production of IL-17 that is 
suppressed by IL-12 (Hoeve, Savage et al. 2006). IL-17 has been shown to 
have important effector activities in autoimmune inflammation, whilst 
IFN-Ȗ KDV EHHQ UHFHQWO\ DWWULEXWHG D PRGXODWRU\ IXQFWLRQ OLPLWLQJ 7K
responses (Harrington, Hatton et al. 2005; Park, Li et al. 2005; Nakae, 
Iwakura et al. 2007). 
 
NFNB is a transcription factor involved primarily in regulation of cell 
proliferation and apoptosis, immune and inflammatory functions 
(expression of cytokines, chemokines and their receptors, inflammatory 
enzymes, acute phase proteins, adhesion molecules etc). It is a 
heterodimeric protein complex consisting of subunits p65 and p50 with 
other variants. NFNB is found inactive in the cytosol bound to inhibitory 
proteins INBs. Signalling activates INB kinases that degrade INB, allowing 
NFNB activation (Perkins 2007). Activated NFNB translocates into the 
nucleus and binds to DNA targets, such as promoters and enhancers, 
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inducing transcription. NFNB is involved in cellular responses to a number 
of inflammatory and infectious stimuli. Among other pathways, SP 
VLJQDOOLQJ YLD 1)ț% KDV EHHQ VKRZQ (Takahashi et al. 1992; Lieb et al. 
1997)DGGLWLRQDOO\KXPDQ1.5SURPRWHUUHJLRQKDVDIXQFWLRQDO1)ț%
binding site (Takahashi et al. 1992; Simeonidis et al. 2003) DQG1)ț%KDV
been shown responsible for mediating NK1R expression (Simeonidis et al. 
2003) ,Q WKLV FKDSWHU ZH KDYH XVHG 1)ț% VLJQDOOLQJ KHOSLQJ WR
substantiate the effects of some of the cytokines. 
 
From the literature, SP mRNA induction has been previously reported by 
IL-12 via STAT4 in murine macrophages (Arsenescu et al. 2005) and 
NK1R upregulation by IL-12 and IL-YLD1)ț%DFWLYDWLRQLQPurine T 
cells (Weinstock et al. 2003). The significance of IL-23/IL-17 axis on SP 
and NK1R has not been investigated. The above effects have not been 
studied in humans. Here we are investigating the responses of SP and 
NK1R to Th1 and Th17 pathways in the human system both on the mRNA 
and protein level using T blasts, CD4+ cells and CD3 and CD28 
costimulated T cells. Additionally, NK1R induction on the promoter level 
is studied in Jurkat cells. 
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4.2 Methods 
4.2.1 Cell preparations and cultures 
PBMC from healthy donors were isolated by standard gradient 
centrifugation as described above (section 3.2.1). For T cell differentiation, 
3%0& ZHUH FXOWXUHG IRU  KRXUV ZLWK  ȝJPO SK\WRKHPDJJOXWLQLQ
(PHA-P, Sigma-Aldrich, UK) in 10% FCS/RPMI media (consisting of 
2mM glutamine, 20mM Hepes, 0.1 mg/ml penicillin and streptomycin) at 
37 qC, 5% CO2. Following PHA-induced proliferation and media change 
cells were stimulated with 1000 U/ml IL-3HSUR7HFK(&8.DW&
5% CO2  for 24 h. 
CD4+ cells were isolated using RosetteSep Human CD4+ T cell 
(QULFKPHQW &RFNWDLO IROORZLQJ WKH PDQXIDFWXUHU¶V SURWRFRO 6WHP&HOO
Technologies, Canada).  
Jurkat T cell line (kindly donated by Professor David Heery, School of 
Pharmacy, University of Nottingham) was used for NK1R promoter-
reporter assay. 
 
4.2.2 Stimulation of cell cultures 
Subsequent stimulations with cytokines were carried out at specified final 
concentrations. Cultured cells 106/ml/well in 10% FCS/RPMI were 
stimulated with 10ng/ml IL-12 (R&D Systems, UK) with and without 2.5 
ȝJPO DQWL-IFN-Ȗ DQWLERG\ 3HSUR7HFK (& 8.  QJPO ,/-23 (R&D 
6\VWHPVZLWKDQGZLWKRXWȝJPODQWL-IL-17 antibody (PeproTech), 10 
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ng/ml IL-17 (PeproTech), 10 ng/ml IFN-J (PeproTech) for 8 and 24 h for 
mRNA-level and 24 and 48 h for protein-level expression.  
 
Anti-CD3 and anti-CD28 stimulation of CD4+ cells was carried out on 24-
well plates that were prepared as follows. Wells of the 24-well plate were 
SUHFRDWHGZLWKȝOZHOO RI WKHPL[WXUH FRQVLVWLQJȝJPO DQWL-CD3 
%HFNPDQ&RXOWHUDQGȝJPODQWL-CD28 (Beckman Coulter, USA) in 
PBS, and kept overnight at room temperature. Wells were washed with 
1ml RPMI. Subsequently, 106 CD4+ cells/ml (isolated as in 4.2.1) were 
transferred to each precoated well and stimulated with IL-12 10 ng/ml or 
IL-23 10ng/ml for 24 hours. 
 
4.2.3 Flow cytometry for protein level expression of NK1R in T cell 
blasts 
Stimulated T cell blasts were washed twice with PBA (Phosphate Buffered 
Albumin, containing 0.5% bovine serum albumin, 0.1% sodium azide in 
phosphate buffered saline), stained with polyclonal primary NK1R 
antibody (Abcam, UK) in 1:50 dilution and incubated in the dark at room 
temperature for 30 mins. Cells were washed twice with PBA and 
subsequently stained with conjugated antibodies: secondary anti-rabbit 
IgG-PE (Abcam, UK) 1:50 and CD3-PC7 (Beckman Coulter, USA) in the 
dark at room temperature for 30 min. Cells were washed twice with PBA, 
fixed with 0.5 ml of 0.5% formaldehyde and analysed. 
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For intracellular staining, stimulated and PBA washed PHA/IL-2 induced 
T cell blasts were incubated in the dark at room temperature with 
conjugated anti-CD3-PC7 (Beckman Coulter) for 40 min and fixed with 
2% formaldehyde for 5 min. Thereafter cells were washed with PBA and 
treated twice with PBA/saponin (0.4 g/l saponin, 50mM glucose in PBA) 
and 10% FCS/saponin (10% FCS in PBA/saponin) buffers and stained with 
primary NK1R antibody 1:50 for 1.5 hours in the dark on ice. Cells were 
washed with PBA/saponin buffer and subsequently incubated with PE-
conjugated secondary NK1R antibody 1:50 for 30 min on ice, washed with 
PBA/saponin and fixed with 0.5 ml 0.5% formaldehyde. T blasts were 
evaluated on EPICS Altra flow cytometer (Beckman Coulter, USA) and 
the results analysed with WinMDI 2.9 software. 
 
4.2.4 ELISA for SP in T cell blasts 
Supernatants of T blast cultures stimulated for 12 and 24 h for the above 
FACS experiments were frozen promptly after collection and stored in -
&2Q WKHGD\RI WKHDVVD\VDPSOHVZHUH WKDZHGDQGDQDO\VHGXVLQJ
WKH 3DUDPHWHU 6P ELISA kit (R&D Systems, USA) according to the 
PDQXIDFWXUHU¶VLQVWUXFWLRQVAdditional serial dilutions were included with 
the lowest standards diluted down to 9.75 pg/ml. The mean minimum 
detectable dose of SP as specified by the manufacturer in these assays was 
Vilisaar, J. 
 66 
31.5 pg/ml.  Paired stimulation sets for 24 h and 48 h were simultaneously 
analysed on the same plate. 
 
4.2.5 Total RNA extraction and reverse transcription 
Total-RNA was extracted by column extraction using RNeasy Miniprep 
.LW 4LDJHQ IROORZLQJ WKH Nit protocol. The homogenization step was 
performed by needle homogenization. The total RNA concentration was 
GHWHUPLQHG DW QP XVLQJ 1DQR'URS 1'-1000 spectrophotometer 
(NanoDrop Technologies). For reverse transcription the same amount of 
total RNA per extraction within the range of 0.3-JZDVLQFXEDWHGZLWK
ȝORIUDQGRPSULPHUVJOLQDILQDOYROXPHRIOZLWKQXFOHDVH-
free water (Sigma-$OGULFKDW&IRUPLQ7KHIROORZLQJFRPSRQHQWV
ZLWK WKH WRWDO YROXPH RI  O ZHUH DGGHG WR HDFK WXEH  ȝO [00/9
UHYHUVHWUDQVFULSWDVHEXIIHU3URPHJDȝOQXFOHRWLGHVP0G$73
G&73 G*73 G873  ȝO ULERQXFOHDVH LQKLELWRU  ȝO 00/9 UHYHUVH
WUDQVFULSWDVH 3URPHJD  ȝO QXFOHDVH-free water, and the mixture 
LQFXEDWHGDW&IRUK7KHUHVXOWDQWF'1$ZDVGLOXWHGZLWKȝORI
nuclease-free water for real time PCR and storage. 
 
4.2.6 Quantitation of TAC1 and NK1R mRNA transcripts 
Quantitative real-time PCR was used to assess TAC1 and NK1R mRNA 
abundance. For real-WLPH 3&5 UHDFWLRQ  ȝO SYBR Green Mastermix 
6WUDWDJHQHȝOQXFOHDVH-IUHHZDWHUȝOIRUZDUGDQGȝOUHYHUVH
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SULPHUV  SPROȝO ZHUH PL[HG ZLWK  ȝO WDUJHW F'1$ZDWHU SHU WXEH
The reaction was carried out in triplicates on multiplex qPCR system 
Mx4000 (Stratagene) ZLWK WKH IROORZLQJ FRQGLWLRQV  PLQXWHV DW Û&
IROORZHG E\  F\FOHV RI DOWHUQDWLQJ Û& IRU  VHFRQGV DQG -Û&
(depending on Tm of primers) for 1 minute. Dissociation curves were 
included for each reaction. For primer design Primer 3 software was used. 
The following oligonucleotides were designed for NK1R: sense 
¶JDDWJDJJDFDJWJDFJDDF¶DQWLVHQVH¶WWJWJJDDFWWJFDJWDJDDF¶IRU7$&
VHQVH ¶WFDDWJJJFDDWJDFDJJWD¶ DQWLVHQVH ¶WFFJFDJWDJFWJDFDFDDF¶
(primer orders from MWG Biotech, Germany). For internal standardization 
ZLWK ȕ-microglobulin the primers were designed as follows: sense 
¶FWFFJWJJFFWWDJFWJWJ¶ DQWLVHQVH ¶WWWJJDJWDFJFWJJDWDJFFW¶ )RU 7$&
UHDFWLRQWKHFRQFHQWUDWLRQRISULPHUVSPROȝODQGWHPSODWHGLOXWLRQV
were used for optimal efficiency. For quantitation of transcripts the relative 
standard curve method (AppliedBiosystems 1997) was used.  
 
4.2.7 Cloning of the NK1R promoter-luciferase expression vector 
The vector for the NK1R promoter activation assay was prepared by 
WUDQVIRUPLQJ ( FROL '+Į ±T1 competent cells (Invitrogen) with human 
NK1R gene promoter 1,837-bp fragment cloned into luciferase expression 
vector pGL3-Basic (Promega, Fig 4.1) (Simeonidis et al. 2003).  
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Figure 4.1.  pGL3-Basic Vector Circle Map.  Description: luc+, cDNA 
encoding modified firefly luciferase; Ampr, gene conferring ampicillin 
resistance in E. coli; f1 ori, origin of replication derived from filamentous 
phage; ori,  origin of replication in E. coli; NK1Rpr, 1837 bp NK1R 
promotor region. Arrows within luc+ and Ampr gene indicate the direction of 
transcription; the arrow in the f1 ori indicates the direction of ssDNA strand 
synthesis (adapted from Promega Product Catalogue, Promega Corporation , 
USA). 
 
ȝJRI WKHFRQVWUXFW JHQHURXVO\SURYLGHGE\&3RWKRXODNLV%HWK ,VUDHO
'HDFRQHVV0HGLFDO&HQWHU%RVWRQ86$ZDVSURSDJDWHGLQWRȝORI(
coli cells with a 2-PLQ Û& KHDWVKRFN 7KH FHOOV ZHUH JURZQ RQ DQ
$PSLFLOOLQ ȝJPO VHOHFWLYH DJDU SODWH RYHUQLJKW DW  Û& $ VLQJOH
colony was isolated and cultured in 2ml of LB media in a shaking 
LQFXEDWRUDWÛ&IRUKDQGWKHUHDIWHUWUDQVIHUUHGLQWRPO/%PHGLD
NK1Rpr 
Vilisaar, J. 
 69 
ZLWK$PSLFLOOLQ ȝJPODQG OHIW VKDNLQJRYHUQLJKW7KHVXVSHQVLRQZDV
centrifuged and DNA extracted using Genelute HP Plasmid Maxiprep kit 
as specified by the manufacturer (Sigma-Aldrich). The concentration of 
SODVPLG'1$ZDVPHDVXUHGE\1DQR'URS1'-1000 spectrophotometer. 
To confirm transformation, restriction digest by endonucleases Kpn1 
(Roche) and BglII (Roche) were used. The promoter construct was 
LQFXEDWHGZLWK8RIHQ]\PHSHUJ'1$LQOFRUUHVSRQGLQJEXIIHU
V\VWHP 5RFKH IRU  K DW & 2Q JHO HOHFWURSKRUHVLV WZR IUDJPHQWV
sized approximately 1.8 Kb and 4.8 Kb (corresponding to the NK1R 
promoter region and the pGL3-Basic vector respectively) were separated in 
the digested extract as compared to the 6.6 Kb undigested control. 
4.2.8 Transfection of Jurkat cells with NK1R promoter-reporter 
construct and luciferase reporter assay 
For incoUSRUDWLRQRIWKHYHFWRULQWR-XUNDWFHOOVî7 FHOOVȝOLFH-cold 
PBS were transferred into each electroporation cuvette (Invitrogen) and 
NHSW RQ LFH IRU  PLQV 6XEVHTXHQWO\  ȝJ SUHSDUHG 1.5 SURPRWHU-
reporter plasmid (containing Photinus pyralis OXFLIHUDVH DQG  ȝJ
Renilla reniformis luciferase reporter vector (Promega) as an incorporation 
FRQWUROZHUHDGGHGSHUFXYHWWHDQGSXOVHGRQ*HQH3XOVHU;FHOO%LRUDG
ZLWK  9 DQG  ȝ) $IWHU HOHFWURSRUDWLRQ FHOOV ZHUH NHSW LQ 
)&6530,RYHUQLJKWDWÛ&&22. 
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Following stimulation of transfected cells with cytokines as above for 24 h, 
FHOOVZHUHZDVKHGZLWK3%6DQGWUDQVIHUUHGLQWR5|KUHQWXEHV6DUVWHGW
Cells were passively lysed according to the Dual-Luciferase Reporter 
Assay protocol (Promega) whilst kept on a shaker for 15 min. The 
lucifearase activities of each lysate were sequentially read on TD-20/20 
single-sample luminometer (Turner Designs) by adding initiation/stop 
reagents (Promega) per protocol. Background luminescence of non-
transfected control was subtracted from individual sample values and ratios 
of Photinus/Renilla luciferase signals were calculated.  
 
4.2.9 Statistical analysis 
For statistical analysis Friedman and Wilcoxon tests, and SPSS 16.0 
software were used. 
4.3 Results 
 
4.3.1 Protein level induction of NK1R in T cell blasts 
NK1R expression on a protein level was studied by flow cytometry using 
surface staining of stimulated PHA/IL-2 blasts; intracellular staining for 
NK1R was tested but in our experiments there was little differential 
staining between samples. 
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Figure 4.2. NK1R surface expression of T cell blasts: mean percentage of T 
blasts surface staining for NK1R from three healthy subjects after 48 h  
stimulation +/- SEM. 
 
The results showed that IL-23 is a relatively strong stimulus with a slightly 
greater effect at 24h than at 48 h. IL-12 effects appeared to be marginally 
stronger after 48 h compared to 24 h. IL-17 proved to be a more effective 
stimulus after 48 h compared to 24 h. IFN-Ȗ ZDV D PRGHUDtely strong 
inducer throughout but is not considerable in mediating IL-12 effects. 
None of the results yielded a statistically significant value. 
Regarding the Th1 pathway effects, the combination of IL-12 10 ng/ml and 
IL-18 10 ng/ml was additionally used in this experiment. Overall, IL-18 
and IL-18/ IL-12 co-stimulation did not show any significant effects. 
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4.3.2 Protein level induction of SP in T cell blasts 
Two separate ELISAs were run on supernatants of stimulated T blasts from 
5 control subjects. Both ELISAs were from R&D with the same sensitivity. 
Protein level SP expression showed a great deal of variability between 
subjects. 
0
2
4
6
8
10
12
14
16
18
20
pg
/m
l
SP 8.22 3.20 8.55 16.37 17.33 9.82 5.15 16.45 3.23
US IL-12
IL-
12+aIFN
g
IL-23
IL-
23+aIL-
17
IFNg IL-17 IL-18 IL-18+IL-12
 
Figure 4.3. A representative example of SP ELISA on one control subject: SP 
concentrations (pg/ml) in T blast culture supernatants following a 24 h 
stimulation. 
 
Overall, IL-23 was a relatively weak stimulus and appeared no more potent 
than IL-12, compared both at 24 h and 48 h. Anti-IL-17 did not show 
blocking effects of IL-23 in these experiments as has also been observed 
on the same individual sets in our flow cytometry data for NK1R.  
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IL-18 appeared a stronger stimulus than IL-12 in these experiments, 
whereas IL-18 and IL-12 co-stimulation did not show any additive effects. 
The samples had generally low levels of SP, extrapolation below the 
sensitivity threshold was avoided. None of the stimulation conditions in the 
experiments gave a statistically significant result. 
 
4.3.3 Induction of SP and NK1R mRNA in T cells 
The effects of Th1 and Th17 stimuli on SP precursor and NK1R expression 
on the mRNA level were studied in T cell blasts from 10 healthy 
volunteers. IL-23 significantly upregulated both NK1R (p=0.041) and 
TAC1 transcripts (p=0.022).  
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Figure 4.4. mRNA-level expression of NK1R relative to the internal standard 
ȕ0*LQ7EODVWVPHDQUDWLRVRIVWLPXODWLRQDVVD\VIURPKHDOWK\FRQWUROV
+/- SEM. 
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There was a trend with IL-12 upregulating TAC1 and NK1R but this did 
not reach the significance level (Figs 4.4, 4.5). NK1R (p=0.037) but not 
TAC1 (p=0.203) expression was significantly upregulated also by IL-17. 
Interestingly, anti-IL-17 abolished the effects of IL-23 in our assays to 
induce TAC1 (p=0.041), whereas this effect was not significant with 
NK1R (p=0.262) (Fig. 4.5). 
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Figure 4.5.  mRNA-level expression of TAC1 relative to the internal standard 
ȕ0* LQ 7 EODVWV IURP  KHDOWK\ FRQWUROV PHDQ UDWLRV RI  VWLPXODWLRQ
assays  +/-  SEM. 
 
On the other hand, anti-IFN-J did not show significant blocking effects in 
IL-12 stimulated samples. There was a trend for IFN-J to upregulate TAC1 
and NK1R but these effects were not significant. 
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In CD4+ cells and anti-CD3/anti-CD28 activated cells stimulation with IL-
12 and IL-23 showed similar results upregulating NK1R and SP precursor 
on the mRNA level.  
 
The above effects were studied over different stimulation periods as it has 
been suggested that IL-12 and IL-23 responses may prevail at different 
stages of inflammation (Thakker et al. 2007). Stimulation for 8 and 24 h 
was used as possible induction of secondary cytokines to IL-12 and IL-23 
stimuli may take time to initiate, however, no differences were found in T 
blasts between 8 h and 24 h. The results from a 4 hour-stimulation as used 
by Weinstock et al (Weinstock et al. 2003) and Arsenescu et al (Arsenescu 
et al. 2005) were also not significantly different from the effects at 8 and 
24 h. However, in CD4+ cells a marginally greater tendency for NK1R 
induction by IL-12 was seen at 24 h compared to 8 h (Fig. 4.6), and in SP 
induction by IL-23 at 8 h as opposed to 24 h (Fig. 4.7). NK1R induction by 
IL-23 in CD4+ cells was significant (p= 0.043), whereas induction by IL-
12 was not, despite a strong trend (p=0.063). TAC1 did not show a 
significant induction neither by IL-23 or IL-12 using non-parametric tests.  
 
With regards to multiple splice variants of TAC1 that have caused 
difficulties in designing primers and optimising reaction conditions, we 
have designed primers inside TAC1 exon 7 (present in all splice variants) 
for the reported results. Real-time PCR dissociation curves were routinely 
Vilisaar, J. 
 76 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
N
K
1R
/b
2M
G
8 h 0.64 0.87 0.96
24 h 0.72 1.01 0.95
US 8h/24h IL-12 8h/24h IL-23 8h/24h
 
Figure 4.6. Mean ratios of NK1R/b2MG mRNA-level expression in CD4+ 
cells at 8h and 24 h: mean ratios of 4 controls +/- SEM. 
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Figure 4.7. Mean ratios of TAC1/b2MG mRNA-level expression +/-SEM of 4 
CD4+ cell stimulation assays for 8 h and 24 h. 
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included for each reaction to detect genomic DNA amplification. On 
agarose gel electrophoresis homogenous product with the expected size 
288bp was detected and the no reverse transcriptase control did not yield a 
band suggesting there was no genomic DNA contamination.  
 
4.3.4 NK1R promoter construct activation in Jurkat cells 
Two experiments were carried out in which IL-23 appears to be an inducer 
of the NK1R promoter region with a 6-fold increase in the reporter signal 
ratio compared to the unstimulated cells. In both of these experiments anti-
IL-17 in IL-23 stimulated samples showed strong reduction of NK1R 
expression compared to the IL-23 stimulus alone (Fig. 4.8). 
0,00
0,10
0,20
0,30
0,40
0,50
0,60
0,70
0,80
0,90
Photinus/Renilla 0,13 0,07 0,22 0,84 0,30 0,13 0,27 0,29 0,36
US IL-12
IL-
12+aIFN
g
IL-23
IL-
23+aIL-
17
IFNg IL-17 IL-18 IL-18+IL-12
  
Figure 4.8. Dual-luciferase reporter assay with activation of NK1R 
promoter-reporter construct in Jurkat cells. The results represent mean 
ratios of Photinus/Renilla luminescence of two experiments after 24 h 
stimulation. 
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IL-12 and IFN-ȖVKRZHGQRDFWLYDWLRQLQWKHVHDVVD\V,/-17, IL-18 and the 
combination of IL-12 and IL-18 showed moderate effects with 2.1, 2.3 and 
2.8-fold increase from the baseline respectively. 
 
As a general comment to the results in this chapter, overall a great deal of 
variability was observed in induction of SP and its receptor. The results 
show marked interindividual variability of SP and NK1R response to 
inflammatory stimuli. There appear to be different responses to IL-12 and 
IL-23 between individuals, more marked with IL-12.  
4.4 Discussion 
IL-23 upregulates both NK1R and SP mRNA and appears to be a much 
stronger stimulus than IL-12 in human T cells. Whereas IL-12 can act on 
ERWK QDwYH DQG DFWLYDWHG FHOOV PDLQO\ DFWLYDWHG FHOOV DUH FRQVLGHUHG
responsive to IL-23 (Parham et al. 2002). Our results can be interpreted in 
the view of this preference to IL-23/IL-17 axis in activated cells, however, 
this hypothesis was tested in a population of CD4+ cells with similar 
tendencies (please see below). IL-17 stimulus was significant for NK1R 
but not for SP induction and this effect was also seen on the protein level 
with positive induction of NK1R showing a stronger effect at 48 h. 
Regarding SP response to IL-17, IL-2 used to provide growth and survival 
for T blasts has been found to abolish IL-17 production and induce IFN-Ȗ
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production (Veldhoen et al. 2006). Despite a strong trend, IFN-J induction 
did not reach the significance level either for NK1R or SP. The results 
showed high unstimulated baseline values which can decrease sensitivity 
and may, however, indicate some dependence of this induction on the level 
of T cell activation. 
 
The above effects studied in CD4+ population and in anti-CD3/anti-CD28 
activated cells showed no significant differences compared to T blasts, 
apart from some reduction in TAC1 response to IL-23 after 48 h. A 
relatively smaller proportion of CD4+ cells in the IL-12 stimulated cultures 
were probably drived towards Th1 phenotype compared to IL-23 
stimulated samples where Th17 responses initially were prevalent. 
Stimulation with CD3 and CD28 was additionally used as TCR/CD3 
complex and CD28 costimulation has been reported to be optimal for 
1)ț% DFWLYDWLRQ OHDGLQJ WR DFWLYDWLRQ RI 7 FHOOV DQG WUDQVFULSWLRQ RI
different inflammatory mediators (Bettelli et al. 2007). However, 
costimulation by CD28 itself has been shown to have only mild enhancing 
effect on IL-23/IL-17 axis (Liu et al. 2005). 
 
Hence, the level of cell activation is not a fully convincing explanation for 
our results with relatively poor Th1 pathway effects. Another possible 
explanation may transpire from our results with CD4+ cells and NK1R 
surface staining. As seen in 48 h NK1R protein-level induction, IL-12 may 
have a slightly greater effect at 48 h and IL-23 may be more important in 
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the initial response as has been also described previously. However, the 
combination of IL-12 and IL-18 used in the protein level experiments did 
not show any increased or additive effects in our assays at any time-point 
as has previously been reported (Weinstock et al. 2003). Nevertheless, with 
regards to the Th1 pathway with IFN-ȖVKRZLQJVRPHLQGXFWLRQLQ1.5
flow cytometry results may still indicate a positive feedback mechanism in 
which SP stimulates IFN-Ȗ (Blum et al. 1993) and IFN-Ȗ LQ WXUQ
upregulates SP receptor in T cells. 
 
In protein-level experiments SP did not show consistent induction by the 
used cytokines. The blocking effects in IL-23 and IL-12 stimulated 
samples by anti-IL-17 and anti-IFN-ȖUHVSHFWLYHO\ZHUHQRWFOHDUO\HYLGHQW
As anti-IFN-Ȗ DEROLVKHV ,)1-Ȗ DQWL-proliferative effects, the increased 
values seen in IL-12 and anti-IFN-ȖFR-stimulated samples may result from 
increased cell numbers in these wells. IL-18 showed induction only in SP 
ELISA. However, in the rest of the conditions SP and NK1R expression 
agree with each other suggesting that both SP and its receptor are 
simultaneously upregulated. This was confirmed by analysing the same 
sets both for NK1R surface staining and for SP production on ELISA. 
However, it is not worth attributing too much reliability on detected SP 
concentrations in cell culture supernatants as SP is quickly inactivated in 
aquous solutions near a physiological pH. Low actual concentrations of SP 
are also not surprising as T cells are not a major source of SP. The 
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discrepancies between the protein and mRNA level induction will be 
discussed below. 
 
Particularly in mRNA-level experiments unstimulated samples showed 
relatively high baseline values and a great deal of variability was observed 
between individual assays from different subjects. Although 10 different 
assays were compared for mRNA-level expression, high baseline values 
may be one of the reasons why some of the conditions showing a strong 
trend, such as IL-12, proved insignificant. To optimise the protocol, 
starving of cells overnight with RPMI without antigenic stimuli of FCS 
was tested. This did not show major differences compared to unstarved 
cells. Higher IL-12 and IL-23 concentrations of 100 ng/ml as opposed to 
10 ng/ml also showed no significant differences in results and were 
suggesting 10 ng/ml as being optimal. With E2MG as an internal standard 
similar pattern was observed with uniformly high values in unstimulated 
samples and throughout the stimulation conditions as expected, however, 
the variation was less between individual assays. This suggests that the 
regulation of TAC1 and NK1R transcripts is variable.  
 
Individual variations were found similarly with NK1R and TAC1, however, 
they were more pronounced with the latter. This is expected as there are 
more factors involved in TAC1 transcriptional and post-transcriptional 
regulation providing a source for variation. These factors include also 
recently uncovered transcriptional silencers repressing TAC1 transcription 
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in non-neuronal cells (Greco et al. 2007). From the literature, much of this 
regulation at the transcription level has not yet been elucidated. Within 
H[RQLQ7$&SURPRWHUUHJLRQDGMDFHQWWR1)ț%VLWHWZR5(-1 silencer 
of transcription (REST) binding sites have been identified (Greco et al. 
2007). Additionally RNA-binding proteins and microRNAs (miRNAs) 
have been shown to regulate SP synthesis (Greco et al. 2007; Murthy et al. 
2008). Although TAC1 mRNA is found ubiquitously in human non-
neuronal tissues (Pinto et al. 2004), some recent studies suggest the 
importance of preconditioning non-neuronal cells with inflammatory 
stimuli for TAC1 expression. Recently, IL-Į has been shown to induce 
TAC1 and particularly SP translation in non-neuronal cells (Greco et al. 
2007). The above findings can explain the lesser degree of protein-level 
expression in our experiments compared to the promoter and mRNA-level 
results as well as contribute to the variability. 
 
Both NK1R and TAC1 promoter regions have NFțB binding sites that 
suggests their activation by immune mediators and role in inflammation. 
The dependence of SP and NK1R expression on Th17 and Th1 stimuli 
further supports SP role in autoimmune inflammation. Here we are 
showing that NK1R promoter is activated by IL-23 and, as suggestive by 
anti-IL-17 blocking effects, also by IL-17. Both IL-23 and IL-17 are 
known to signal via NFțB, consistent with our promoter-level findings. 
Additionally, IL-18 showed similar moderate effects as IL-17 on the 
promoter level. In the work by Weinstock (Weinstock et al. 2003) and 
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Arsenescu (Arsenescu et al. 2005) NK1R expression was induced by IL-12 
and IL-18 in murine T cells via NFțB, whereas SP induction in murine 
macrophages was responsive only to IL-12 via STAT4. In our study, the 
effects of IL-18 and co-stimulation of IL-12 and IL-18 activating NK1R 
promoter were nearly 2.5 fold less than the effects by IL-23. IL-12 alone 
gave no activation of NFțB-containing NK1R promoter whilst known to 
act via STAT4. SP synthesis has been previously shown to be STAT4 
independent (Blum et al. 2008). These findings support SP involvement in 
the Th17 pathway.  
 
Regarding other published studies, IL-12 has been shown to induce SP 
which can mediate IFN-J production potentiating IL-12 effects in murine 
cells (Blum et al. 1993; Blum et al. 2001). Also due to the described effects 
above SP has been so far suggested to be part of Th1 pathway. In the 
recent study IL-12 was shown to induce SP in murine T cells whereas IL-
23 induced SP in macrophages (Blum et al. 2008). In our study IL-12 
induction of SP nor NK1R was significant in human T cells. As evidence 
suggests from our experiments, this induction of SP by IL-12 is likely not 
additionally mediated by IFN-J. As part of the IL-12 immune regulatory 
circuit SP has been also shown to induce IFN-J in antigen-driven T cells in 
murine schistosomiasis (Blum et al. 1993). In our work the speculative 
positive feedback effect by IFN-J inducing SP itself, was not confirmed. 
Importantly, also in the above-mentioned work by Weinstock (Weinstock 
et al. 2003) and Arsenescu (Arsenescu et al. 2005) the effects in murine 
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cells were dependent on the presence of Schistosoma mansoni in the 
inflammatory model. NK1R upregulation has also been demonstrated by 
IL-1ȕDQG71)Į via NFțB in murine macrophages (Simeonidis et al. 2003) 
which in our study was not investigated. IL-1E via NFțB has also been 
shown to upregulate NK1R in astrocytes (Guo et al. 2004). 
 
On the basis of our similar results in T blasts as well as anti-CD3/anti-
CD28 activated cells one can conclude that SP and its receptor in T cells 
respond to Th17 stimuli and less so to Th1-type signals. Additionally, IL-
23 potent activation of NK1R promoter region was shown in Jurkat cells. 
IL-23 effects as part of the Th17 response may be particularly relevant in 
the early inflammatory response whereas IL-12 as part of the Th1 cascade 
may be more important at later stages. IL-23 strong effect is likely a co-
effect accomplished via involvement of Th17 population with IL-17 
production that additionally mediates IL-23 effects. IL-12 effects in human 
T cells did not prove to be mediated by IFN-Ȗ The results support SP and 
its receptor involvement in IL-23/IL-17 axis responses that have been 
shown important in the inflammatory model of EAE. 
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5 Upregulation of substance P and its receptor in human NT2 
neurons via functional IL-17 receptor 
5.1  Introduction 
Human NTera2 (NT2) cells are neuronally differentiated teratocarcinoma-
derived cells that are among very few available neuronal cell lines with the 
terminal phenotype virtually identical to mature primary neurons. NT2 
cells are differentiated into post-mitotic neurons (NT2N) involving 
treatment with retinoic acid (RA) (Andrews 1984). Exposure of NT2 cells 
to RA over a 6-week period downregulates neuro-epithelial markers and 
upregulates neuronal markers on them (Pleasure et al. 1992; Pleasure et al. 
1993). Further exposure to mitotic inhibitors (MI) produces 99% pure 
population of terminally differentiated NT2N (Lee 1986). They produce 
outgrowth processes and form functional synapses, express all three classes 
of neurofilaments (Lee 1986), microtubule associated proteins type 1 and 2, 
tau protein, synaptophysin (Pleasure et al. 1992) as features characteristic 
of CNS neurons. Immunocytochemically terminally differentiated NT2N 
do not divide and maintain their neuronal phenotype over long time 
periods (Pleasure et al. 1993). 
 
Evidence exists on SP role in CNS immune regulation and modulation of 
neuronal functions related to immune activities in the CNS (Li et al. 2003). 
Multiple cell types in the CNS express NK1R, such as neurons, astrocytes, 
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microglia, oligodendrocytes which produce cytokines in response to SP 
(Martin et al. 1993; Gitter et al. 1994; Luber-Narod et al. 1994; Li et al. 
2003)(Marriott 2004). Neuroimmune interactions involving SP may be 
particularly relevant in inflammation-induced neuronal injury as occurs in 
an acute MS relapse. SP expression in neurons has been shown 
downregulated in neuronal injury (Hokfelt et al. 1994), at the same time SP 
receptor binding sites are highly expressed in glia in vivo after neuronal 
injury (Mantyh et al. 1989). This and SP immunoreactivity found in MS 
plaques (Kostyk et al. 1989) may suggest possible SP regulation of glial 
response to injury. Signalling of NK1R has been shown to lead to NFNB 
activation in the CNS and upregulation of inflammatory mediators (Lieb et 
al. 1997; Wang et al. 2004). 
   
The expression of SP and NK1R has been previously confirmed in NT2N 
(Li et al. 2003). Transcripts for both SP precursor and NK1R mRNA have 
been shown to be present in NT2N with increase in their expression during 
NT2 differentiation (Li et al. 2003). On the protein-level, NK1R has been 
confirmed in NT2N cell membranes, and SP demonstrated intracellularly 
by immunohistochemical and immunofluorescent staining techniques (Li 
et al. 2003). Levels of SP expression have been found higher in NT2N 
compared to human monocytes, peripheral blood lymphocytes and 
microglia (Li et al. 2003). NK1R functional expression in NT2N has been 
previously confirmed with SP induction of macrophage inflammatory 
protein-1E (MIP-1E) (Li et al. 2003). SP has been shown to activate NFNB 
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promoter in NT2N (Wang et al. 2004), the mechanism that may explain 
regulation of chemotaxis and a variety of other pro-inflammatory gene 
functions by SP. 
 
NT2N represent a good model for studying neuronal gene expression in 
response to inflammatory stimuli, and substantial evidence exists on 
neurons and NT2N being involved in inflammatory responses. Several 
inflammatory mediators and their receptors have been demonstrated on 
NT2N. In addition to MIP-1E (Li et al. 2003), NT2N are also known to 
produce MCP-1 and express functional receptors for a range of 
chemokines including CCR1, CCR2, CCR5, CXCR1, CXCR2, CXCR3, 
CXCR4 (Hesselgesser et al. 1997; Coughlan et al. 2000; Valerio et al. 
2004; Lu et al. 2005). IL-8, MCP-1, RANTES and IP-10 production by 
NT2N have been reported on hypoxia and subsequent reoxygenation 
(Froyland et al. 2006). Additionally, IL-1E has been shown to stimulate 
MIP-1D and -1E production by NT2N (Guo et al. 2003), and IL-1E and 
TNF-D have shown effects on GM-CSF production in NT2N (Dame et al. 
2002). 
 
IFN-J, an important Th1 cytokine in MS pathogenesis, has established 
reception and effects on NT2N. IFN-Ȗ HIIHFWV KDYH EHHQ VKRZQ WR
implement in the CNS via IFN-Ȗ UHFHSWRU DQG DOSKD-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic (AMPA) receptor subunit GluR1 complex 
(Mizuno et al. 2008). Activation of this receptor complex leads to JAK1,2 
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and STAT1 pathway activation. Previously demonstrated neurotoxic 
effects of IFN-J have been shown both mediated via microglial reaction, 
and directly on neurons. IFN-J effects on neurons have, however, been 
reported contradictory, inducing retrograde dendritic retraction, inhibiting 
synapse formation (Kim et al. 2002) as well as promoting neurite 
outgrowth and survival of neuronal cells (Barish et al. 1991; Song et al. 
2005). In mouse cortical neurons IFN-J has shown direct induction of 
neuronal dysfunction with dendritic bead formation and enhancing 
glutamate neurotoxicity via AMPA receptors (Mizuno et al. 2008). It has 
been proposed that the direct mechanism of IFN-J neuronal excitotoxicity 
could contribute to neuronal dysfunction in inflammatory and 
neurodegenerative diseases.  
 
Much less is known about Th17 effects on neurons and neuronal response 
to Th17 in CNS inflammation. IL-17 (IL-17A) as the main effector 
cytokine in Th17 responses in MS lesions has various effects and target 
functions. However, no studies have yet shown IL-17 direct effects on 
neurons, which may have important implications, including inflammatory 
neurodegeneration. IL-17 binds to both IL-17A receptor (IL-17RA) and 
IL-17RC that form oligomeric IL-17 receptor (IL-17R) complexes. IL-17R 
has been shown to consist of at least two IL-17RA subunits and at least one 
IL-17RC, however, the precise stoichiometry of the receptor complex has 
not been determined (Shen et al. 2008). IL-17R expression on neurons has 
not been shown unequivocally. Limited evidence is available to date about 
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IL-17R downstream signalling, in which NFNB is most frequently 
implicated alongside with MAPK, less so JAK-STAT and other pathways 
(Shen et al. 2008). The main propotion of IL-17 signal regulated target 
genes involve different inflammatory mediators, often regulated 
synergistically with other cytokines (Shen et al. 2008). No reports have 
been made on IL-17 effects on SP or NK1R expression. 
 
In this chapter we have been studying the regulation of SP and NK1R 
expression in neurons in response to inflammatory stimuli as an aspect of 
autoimmune inflammation in the CNS. Considering different expression of 
SP and NK1R in the CNS compared to peripheral immune cells, as well as 
co-effects with other mediators, SP immunogenic effects in the CNS may 
be different. We have previously shown that SP and NK1R are upregulated 
in human T cells differentially by Th17 and Th1 stimuli. Here we studied 
some of these effects on NT2N. We measured IL-17 functional effects on 
SP and its receptor expression in these cells and compared them with the 
well-established stimulus of IFN-J. To substantiate IL-17 direct effects we 
additionally addressed the IL-17R expression on NT2N. We have also 
studied the effects of SP on neuronal expression of IL-17RA, IL-17 and 
NK1R. As part of studying SP and NK1R expression in NT2N, we are 
investigating with this approach also direct neuronal response to IL-17, as 
a key cytokine in CNS inflammation. TAC1 has also been used previously 
as a target in studying general questions of neuronal gene expression 
(Greco et al. 2007). 
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5.2 Methods 
5.2.1 Preparation of undifferentiated NT2 (NT2U) cultures 
Frozen stock of NT2U teratocarcinoma cells were thawed, immediately 
DGGHG WR  PO RI ZDUP '0(0 'XOEHFFR¶V 0RGLILHG (DJOH 0HGLXP
Invitrogen, USA) with 10% FBS (Fetal Bovine Serum), 1% 
Penicillin/Streptomycin (P/S) and centrifuged for 7 min at 2000 rpm. Cell 
pellet was resuspended in 6 ml DMEM with 10% FBS, 1% P/S and 
LQFXEDWHG LQ 7 WLVVXH IODVNV DW &  &2 :KHQ FRQIOXHQW FHOOV
were washed with 5ml Versene (8g NaCl, 0.2g KCl, 1.15g Na2HPO4 0.2 
EDTA, 0.1 g Phenol Red), treated with 2 ml of 0.25% Trypsin (Invitrogen, 
USA) in PBS and incubated in T75 flasks in a total of 18 ml of DMEM 
with 10% FBS, 1% P/S, and maintained by twice weekly passages. 
 
5.2.2 Differentiation of NT2U into mature post-mitotic neurons 
2.7 x106 178FHOOVZHUHUHSODWHGLQWRȝ0UHWLQRLFDFLG5$LQDWRWDO
of 18 ml DMEM with 10% FBS, 1% P/S per T75 flask for a 5-week 
incubation with twice weekly replating and RA media change. At week 5 
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FHOOV ZHUH UHSODWHG LQWR PLWRWLF LQKLELWRUV 0,  ȝ0 -fluoro-¶-
GHR[\XULGLQHȝ0XULGLQHȝ0F\WRVLQH-ȕ-D-arabino furanoside) with 
weekly MI media change and replating in either of the following two ways: 
1. The total number of cells from one T75 flask were incubated in MI 
media on 6-well tissue culture plates (7 in total) for 4 weeks to 
reach full maturity. This method is slower, allowing neurons to 
grow on the bed of existing background cells, but is more 
consistent in methodology; 
2. Alternatively, contents of one T75 flask was cultured in 10 cm Petri 
dishes (9 in total) in MI media for 6-9 days. Cells were washed 
WZLFH ZLWK +%66 [ +DQN¶V %DODQFHG 6DOW 6ROXWLRQ 0HGLDWHFK
Inc, USA), treated with 2 ml trypsin to break cell adhesions and 
suspension centrifuged. Cell pellets were triturated 15-20 times 
through a Pasteur pipette, cells counted and cultured 106 cells in 
2ml of MI media on 35 mm Matrigel covered dishes for terminal 
differentiation for 1-2 days. This method is faster yielding a 95-
98% pure population of differentiated neurons in a relatively short 
time using an artificially provided extracellular matrix substrate 
(Matrigel). 
 
5.2.3 Stimulation of cell cultures 
Cells were assessed under confocal microscopy for differentiation, 
viability and cell density. MI media overlying terminally differentiated 
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NT2N neurons on 6 well plates was measured and reduced to 2ml. Cell 
cultures were stimulated with/without human IL-17 (R&D Systems) 10 
ng/ml or 100ng/ml, IFN-ȖQJPORUQJPODQG636LJPD-Aldrich) 
10-5 or 10 ±6 0DQGLQFXEDWHGDWÛ&&2IRUKRU 48h. To confrm 
IL-5PHGLDWHGHIIHFWVQHJDWLYHFRQWUROVZLWKKHDW LQDFWLYDWHGÛ&IRU
10 min) IL-17 100 ng/ml and anti-IL-17RA were additionally used. 
 
5.2.4 Total RNA extraction 
Media on stimulated cells were removed and cells washed twice with 
HBSS. Wells ZHUH VXEVHTXHQWO\ FRYHUHG ZLWK ȝO RI 7U\SVLQ DQG WKH
plates tapped to detach neurons (2-3 min) assessing under a confocal 
microscope. 1 ml of DMEM media was immediately added and cell 
suspension transferred into eppendorfs. Total-RNA extraction was 
perfRUPHG XVLQJ 51HDV\ 0LQLSUHS .LW 4LDJHQ DFFRUGLQJ WR WKH
PDQXIDFWXUHU¶VLQVWUXFWLRQV([WUDFWHGWRWDO-RNA amounts were quantified 
using BioPhotometer 6131 (Eppendorf AG, Germany). Purity was assessed 
by measuring the 260/280 nm ratio, samples within range 1.0-2.5 range 
were used.  
 
5.2.5 Reverse transcription 
ȝJRIWRWDO51$ZDVLQFXEDWHGZLWKȝORIUDQGRPSULPHUVJO
LQDILQDOYROXPHRIOZLWKQXFOHDVH-IUHHZDWHUDW&IRUPLQ)RU
UHYHUVH WUDQVFULSWDVH VWHS ȝO [ 00/9 UHYHUVH WUDQVFULSWDVH EXIIHU
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3URPHJD  ȝO RI QXFOHRWLGHV P0 dATP, dCTP, dGTP, dUTP), 
ȝO ULERQXFOHDVH LQKLELWRU 3URPHJD ȝO 00/9 UHYHUVH WUDQVFULSWDVH
3URPHJD DQG  ȝO QXFOHDVH IUHH ZDWHU DV D PL[WXUH ZDV DGGHG LQWR
each of the microcentrifuge tubes, whilst on ice. The tubes were incubated 
DWÛ&IRUK$WWKLVVWDJHF'1$ZDVGLOXWHGWRȝOZLWKQXFOHDVH
free water for the subsequent real-time PCR step. 
 
5.2.6 Quantitation of IL-17A, IL-17RA, NK1R, PPT mRNA transcripts 
Quantitative real-time PCR was used to assess mRNA abundance for the 
above genes and 18S RNA as a housekeeping gene for internal 
standardisation. For a real-WLPH 3&5 UHDFWLRQ  ȝO 6<%5 *UHHQ
0DVWHUPL[6WUDWDJHQHȝOQXFOHDVH-IUHHZDWHUȝOIRUZDUGDQG
ȝO UHYHUVH SULPHUV  SPROȝO ZHUH PL[HG ZLWK  ȝO WDUJHW F'1$ZDWHU
per tube. The reaction was carried out in triplicates on multiplex qPCR 
system Mx4000 (Stratagene) with the following conditions: 10 minutes at 
Û& IROORZHG E\  F\FOHV RI DOWHUQDWLQJ Û& IRU  VHFRQGV DQG -
Û& GHSHQGLQJ RQ 7m of primers) for 1 minute. The following primers 
ZHUH XVHG 1.5 VHQVH ¶JDDWJDJJDFDJWJDFJDDF¶ DQWLVHQVH
¶WWJWJJDDFWWJFDJWDJDDF¶ 7$& VHQVH ¶WFDDWJJJFDDWJDFDJJWD¶
DQWLVHQVH ¶WFFJFDJWDJFWJDFDFDDF¶ ,/-17RA sense 
¶FDFFJWJJDJDFFFWJJDJJF¶ DQWLVHQVH ¶JWFWJJJFJFDJJWDWJWJJ¶ ,/-17A 
VHQVH ¶JFDFDDDFWFDWFFDWFFF¶ DQWLVHQVH ¶JWJDWWFFWJFFWWFDFWDWJ¶ 6
51$VHQVH¶FJJFWDFFDFDWFFDDJJDD¶DQWLVHQVH¶JFWJJDDWWDFFJFJJFW¶ 
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For quantitation of transcripts the relative standard curve method was used. 
For optimal efficiency of the reaction template dilutions 1:5 were used. 
Dissociation profiles were included for each reaction to assess product 
homogeneity. Product sizes were confirmed on agarose gel electrophoresis.
 
5.2.7 Agarose gel electrophoresis 
2.0% agarose gel was prepared with ethidium bromide and samples run at 
100V for 50 min alongside with 100 bp DNA Ladder (Promega, USA) to 
determine product size. 
5.2.8 Western blotting 
Differentiated NT2 cells were washed twice and lysed with 1x RIPA buffer 
(50mM Tris-HCl pH 7.4, 150mM NaCl, 1% NP40, 0.25% Na-
deoxycholate, 1mM PMSF, 1x Roche complete protease inhibitor cocktail, 
1x Pierce phosphatase inhibitor cocktail), lysate was collected and 
transferred into eppendorfs. Protein was quantified with Lowry assay (Bio-
Rad Protein Quantification Assay, Bio-Rad, USA) and read at 750 nm on 
Microplate reader 680 (Bio-Rad). Standard curve (BSA standards in range 
0.25- 2.0 mg/ml) was plotted and total protein concentration determined. 
After denaturing the O\VDWHVIRUPLQDWÛ&ȝJRIWRWDOSURWHLQZDV
run on 7% acrylamide gel in TGS buffer with Prestained SDS-PAGE 
standards (BioRad). Macrophage and CD4+ cell lysates as positive 
controls and NT2U lysates for comparison were treated and run 
accordingly. Following electrophoresis the gel was transferred onto PVDF 
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membrane (Bio-Rad) and run overnight at 30-9DWÛ&7KHPHPEUDQH
was washed, incubated with 5% Blotting Grade Blocker Non-Fat Dry Milk 
(Bio-Rad) in PBS-Tween for 1h and incubated with 1 Pg/ml primary 
mouse antibody (monoclonal) to human IL-17RA (FabGennix Inc, USA) 
in PBS-Tween- SRZGHUHG PLON RYHUQLJKW URFNLQJ DW Û& 7KH
membrane was washed and stained with a secondary goat anti-mouse HRP 
conjugated antibody (Thermo Scientific, USA) 10ng/ml in PBS-Tween-5% 
powdered milk rocking for 1h at room temperature. The membrane was 
washed 5x10 mins and treated for 2 min with chemoluminescent 
6XSHU6LJQDO:HVW'XUD6XEVWUDWH7KHUPR6FLHQWLILF86$DFFRUGLQJWR
WKHPDQXIDFWXUHU¶VLQVWUXFWLRQV7KH membranes were exposed for 1-60 sec 
in the dark and developed. 
 
5.2.9 Subcellular fractionations of NT2 cells 
For whole-cell lysate collection, cells were rinsed twice with ice-cold PBS, 
lysed in 75 mM Tris-HCl (pH 6.8), 15% glycerol, 3.75 mM EDTA, and 
3% SDS, and supplemented with Complete Protease Inhibitor Cocktail 
(Roche Applied Science, USA) and PhosSTOP phosphatase inhibitor 
mixture (Roche). 
7RDVVHVV IRUQXFOHDU WUDQVORFDWLRQRI1)ț%SURWHLQVGLIIHUHQWLDWHGFHOOV
were treated with DMF for 24 h, exposed to TNF-ĮQJPOIRUPLQ
and fractionated. To prepare nuclear extracts, cells were rinsed twice in 
ice-cold PBS and lysed on ice for 10min in 10mM HEPES (pH 7.9), 10 
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mM KCl, 10 mM EDTA, 1 mM DTT, and 0.4% Nonidet P-40 
supplemented with protease and phosphatase inhibitors. Nuclei were 
pelleted for 3 min at 16000 u g and the supernatant (cytoplasmic fraction) 
was collected and stored at ±20 qC. The nuclear pellet was resuspended in 
20 mM HEPES (pH 7.9), 400 mM NaCl, 1 mM EDTA, 10% glycerol, 1 
mM DTT and protease and phosphatase inhibitors and incubated at 4 qC 
on a rocking platform at 200 rpm for 2 h. After centrifugation at 16000 u g 
for 5 min, supernatants (nuclear fractions) were collected and stored at ±20 
C. Protein concentrations were determined and cell lysates were subjected 
to SDS-PAGE as above (Cross et al. 2011). 
5.3 Results 
5.3.1 IL-17R mRNA level expression in neurons 
The mRNA level expression of IL-17RA gene was confirmed in response 
to various stimuli, including IL-17, IFN-ȖDQG63,/-17RA appears to be 
relatively equally upregulated by IL-17 and IFN-Ȗ 7KH VWURQJHVW VLJQDO
according to the real-time PCR results, as also evidenced on gel 
electrophoresis, was seen with IL-17 (Fig 5.1). IL-17 at 10 ng/ml gave a 
2.3-fold increase as compared to a 1.9-fold increase with IFN-ȖQJPO
IL-17 10 ng/ml appeared more effective than 100 ng/ml and the effects of 
IL-17 were greater at 24h than at 48h. The product homogeneity and size 
was confirmed on gel electrophoresis as shown in Fig 5.1. 
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Figure 5.1. Gel electrophoresis confirming homogeneous real-time PCR 
product corresponding to 149 bp IL-17RA amplicon from NT2N under 
different stimulation conditions. Arrows indicate steps of 100 bp DNA ladder 
(Promega, USA). 
 
SP showed a dose dependent effect on IL-17RA expression with SP10-5 M 
giving a 2.3-fold increase from the baseline (Fig 5.2), whereas SP10-6 M 
showed a downregulating effect on IL-17RA mRNA abundance. Due to 
wide baseline variations the results are presented as separate experiments. 
Similar results were obtained in 3 additional experiments. 
1500 
bp 
1000 
100 
Vilisaar, J. 
 98 
0.0
0.5
1.0
1.5
2.0
IL-17R 0.82 1.87 1.55 0.51 1.86
Control IL-17 10 
ng/ml
IFNg 10 
ng/ml
SP 10  ^-
6M
SP 10  ^-
5M
 
Figure 5.2. Representative experiment showing IL-17RA mRNA abundance 
standardised with 18S RNA (arbitrary units) in response to different stimuli 
in a 24h stimulation experiment of NT2N. Similar results were shown in 3 
additional experiments. 
 
5.3.2 Upregulation of neuronal SP and NK1R by IL-17 and IFN-Ȗ 
As an initial control experiment to confirm the specificity of the IL-17RA 
binding, heat-inactivated IL-17 100 ng/ml and monoclonal anti-IL-17RA 
(R&D Systems)  ȝJPO WRJHWKHU ZLWK ,/-17 100 ng/ml in a 24h-
stimulation were tested as negative controls (Fig 5.3). 
IL-17 in this experiment clearly upregulated mRNA level expression 2.4-
fold for NK1R, 1.5-fold for TAC1, and 2.8-fold for IL-17RA, whereas 
heat-inactivated IL-17 effects were comparable with the baseline values. 
IL-17 strongly upregulated its own expression in these cells giving a 5.4-
fold increase. 
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Figure 5.3. Specificity of IL-17 effects on NK1R, TAC1, IL-17RA and IL-17 
expression in NT2N on the basis of one real-time PCR experiment. The 
effects were measured by mRNA abundance and standardised with 18S RNA 
(arbitrary units). 
 
Anti-IL-17RA showed blocking effects on the above expression suggesting 
that the effects were mediated via IL-17RA binding.  
18S RNA was used as an housekeeping gene in NT2N experiments due to 
E2MG expression showing upregulation by IFNJ in NT2N. 
 
On studying TAC1 and NK1R mRNA level expression, IL-17 and IFN-Ȗ
stimuli at different concentrations were used in comparison. Both IL-17 
and IFN-ȖDWQJPOKDGVWURQJHUHIIHFWVWKDQDWQJPO7KHHIIHFWV
were more marked for NK1R (Fig 5.4). 
Vilisaar, J. 
 100 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
NK1R 0.72 0.89 0.38 1.55 0.81
TAC1 0.99 1.10 0.49 1.00 0.64
Control IL-17 10 
ng/ml
IL-17 100 
ng/ml
IFNg 10 
ng/ml
IFNg 100 
ng/ml
 
Figure 5.4. Effects of different doses of IL-17 and IFN-ȖRQ1.5DQG7$&
expression in NT2N: averages of two 24h stimulation sets standardised with 
18S RNA (arbitrary units). 
 
IL-17 effects were stronger at 24h, whereas IFN-Ȗ VKRZHG WUHQG WRZDUGV 
greater effect at 48h (data not shown). IFN-Ȗ LQ WKLV VHULHV DSSHDUHG D
stronger stimulus than IL-17 at the same concentration.  
 
5.3.3 Upregulation of neuronal gene expression by SP 
The effects of SP were studied using two different concentrations i.e. 10-6 
M and 10-5 M of SP. Interestingly, SP stimulus at 10-6 M showed a 
tendency for downregulation of all studied genes, as opposed to SP 10-5 M 
that strongly upregulated IL-17RA, IL-17 and its own expression in 
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neurons, but not NK1R expression (Fig 5.5). SP appeared an equally strong 
stimulus both at 24h and 48h. 
0.0
0.5
1.0
1.5
2.0
2.5
NK1R TAC1 IL-17R IL-17
Control
IL-17 10 ng/ml
IFNg 10 ng/ml
SP 10  ^-6M
SP 10  ^-5M
 
Figure 5.5. Effects of different stimuli on NT2N mRNA level expression 
(arbitrary units) of NK1R, TAC1, IL-17R and IL-17, normalised with 18S 
RNA; representative results of one 24 h stimulation experiment. 
 
5.3.4 Western blotting for IL-17R and NFNB proteins in NT2 neurons 
On WB the product size around the expected 106 kDa, corresponding to 
the IL-17RA, was not convincingly detected. WB was run for both NT2N 
and NT2U cells for comparison. CD4+ T cell and macrophage lysates, 
treated according to the same lysis protocol, were included as positive 
controls. As a positive immunoblot control the membranes were stained for 
ȕ-actin 1:2000 as a primary antibody giving a strong signal after one-
second exposure. 
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As WB results for IL-17RA were not convincing, we have studied NFNB 
as a putative marker for IL-17RA signaling. NT2N fractionation for NFNB 
nuclear versus cytoplasmic localisations was carried out after 24h 
stimulation with 100 ng/ml IL-17. IL-17 did not affect total levels of NFNB 
proteins (p105, p50, p65) or alter their nuclear/cytoplasmic ratios as 
assessed by WB (Fig. 5.6). We have also used TNFD alone and in addition 
to IL-17 on NT2N that neither affected the amount of nuclear NFNB 
proteins. Thus, no evidence has been found to support NFNB signalling in 
neurons as part of the IL-17RA receptor response, nor in response to TNFD, 
as an exploratory experiment. It is possible that IL-17 may signal in 
neurons via other pathways, such as ERK1/2. 
 
 
Figure 5.6. Nuclear fractionation of NT2N and Western blotting. IL-17 
treatment did not induce nuclear entry of NFkB p65 and NFkB p50 proteins. 
GAPDH and PARP serve as positive controls showing good fractionation and 
localisation in cytoplasmic and nuclear compartments respectively. 
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 As a general comment to this section, no differences in results were seen 
from cells grown on Matrigel plates compared to the ones grown on 6-well 
plates. 
5.4 Discussion 
In this chapter we have focussed on the expression of SP and its receptor in 
NT2 cells in response to IL-17 as the main effector cytokine in MS 
pathogenesis. The response of SP and NK1R expression to autoimmune 
inflammation in peripheral immune cells could be similar in neurons, 
however, little is known to date on direct neuronal response to 
inflammatory stimuli. Neuronal mechanisms initiating changes in gene 
expression, resulting in sequelae, including inflammatory 
neurodegeneration, are largely unknown. Although previous studies have 
shown Th1 effects on neurons, no studies to date have demonstrated IL-17 
direct effects on neurons. In our study we have addressed the latter mainly 
by studying changes in gene expression comparatively in response to IL-17 
and other stimuli. The effects of IL-17 on SP and NK1R expression is of 
relevance as SP in the setting of CNS inflammation may serve as an 
important modulator of immune responses.  
 
A number of inflammatory and excitotoxic agents released by immune and 
glial cells in acute MS lesions are known to cause toxic neuronal injury 
and inflammation. As part of Th17 effects on neurons, cytolytic activity by 
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granzyme B, secreted mostly by CD8+ cells, has previously been shown 
(Kebir et al. 2007). The receptor for IL-17 in MS lesions is known to be 
expressed in addition to the immune cells also on astrocytes, thus in vivo 
the effects of IL-17 can be both direct on neurons, and indirect involving 
astrocytes. IL-17 immunoreactivity has also previously been shown on 
astrocytes in MS brain (Tzartos et al. 2008). The current study was 
designed to look at IL-17 effects on pure neuronal population to allow 
more straightforward conclusions on the direct effects. We have addressed 
the expression of IL-17R on these cells, as although there is previous 
suggestion of its presence on neurons (Kebir et al. 2007), it has not been 
confirmed.  
 
IL-17RA mRNA-level expression was confirmed in stimulation 
experiments which showed upregulation of the gene by IL-17, IFN-ȖDQG
SP. IFN-Ȗ XSUHJXODWLQJ ,/-17RA mRNA shows credible evidence of 
neuronal response to an established stimulus of IFN-Ȗ DQG PD\ H[SODLQ
how IFN-Ȗ IDcilitates and enhances Th17 effects in some experimental 
situations (O'Connor et al. 2008). IL-17 upregulating IL-17RA supports the 
importance of Th17 effects and signal reception in neurons. WB was 
additionally used to study protein level expression of IL-17RA on NT2N, 
however, the results were not convincing, despite different stainings used 
for IL-17RA comparing NT2N, NT2U, macrophages and CD4+ cells. 
Generally, our experiments showed little and nonspecific binding for IL-
17RA as one of the receptor subtypes together with IL-17RC for which IL-
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17 is a known ligand. To demonstrate that the observed effects of IL-17 
were indeed implemented via IL-17RA, control stimulations were 
performed with heat-inactivated IL-17 and monoclonal anti-IL-17RA that 
supported the effects via IL-17RA.  
 
Signalling mechanisms of IL-17 receptors are largely unknown. IL-17 has 
been reported to signal via different pathways, most commonly via NFNB. 
The latter has been preliminarily tested in our study in an attempt to further 
support intracellular effects of IL-17 by means of signalling. Nuclear 
versus cytoplasmic fractionation of NFNB proteins with subsequent WB 
was used with no significant activation by IL-17. TNFD, that has an 
established functional receptor on NT2N, was tested additionally as IL-17 
effects are known to be synergized by TNFD. Surprisingly, TNFD 
treatment did not induce nuclear localization of p65 in NT2N, whereas in 
macrophages TNFD treatment strongly increases the amount of nuclear 
NFNB. The results suggest that TNFD may not regulate NFNB nuclear 
import in NT2N. As neither of these cytokines seemed to activate NFNB in 
NT2N it is likely that they act via other pathways, such as ERK1/2. Further 
studies are needed to confirm the structural presence and signalling of IL-
17RA in neurons, however, as being beyond the aims of this project, this 
was not further elucidated. 
 
Representing a Th1 response, stimulation with IFN-Ȗ ZDV LQFOXGHG 
throughout the experiments for comparison with IL-17 effects and 
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validation of NT2N functional response. IFN-Ȗ DV DQ LPSRUWDQW 7K
cytokine in MS pathology has well-characterised effects on neurons (Wong 
et al. 1984; Benveniste 1998; Munoz-Fernandez et al. 1998; Rottenberg et 
al. 2002). In our experiments the effects of IL-17 and IFN-Ȗ ZHUH
comparable, supporting the role of both cytokines on neurons in 
inflammatory settings. In T cells IFN-Ȗ KDV EHHQ VKRZQ WR LQKLELW ,/-17 
expression (Harrington et al. 2005; Park et al. 2005). However, in other 
experimental situations it was shown to increase IL-17R expression, and 
Th1 cells have been shown to facilitate entry of the Th17 into the CNS 
(O'Connor et al. 2008). Also, the subset of T cells co-expressing IFN-J and 
IL-17 are thought to be the most potent inflammatory cells in both EAE 
and MS (Edwards et al.). The suppression of IL-17 by IFN-J was not 
observed in neurons, on the contrary, in our study IFN-ȖXSUHJXODWHG,/-17 
mRNA. Neurons as neuroectodermal cells, may be expected to express IL-
17 and its expression by a variety of neoplastic cells has been reported 
(Kebir et al. 2007). Therefore it is plausible that adult neurons or NT2N 
express IL-17 and that NT2U express higher levels. Based on our results, 
IFN-ȖFRXOGKDYHDUROHLQXSUHJXODWLQJ63DQGLWVUHFHSWRULQWKH&16 
 
The effects of IL-17 on NT2N were more marked for NK1R than for 
TAC1 expression. This indicates that in inflammation IL-17 upregulates 
NK1R, rather than SP, which may be present at high concentrations in 
these settings. Both IL-17 and IFN-Ȗ KDG VWURQJHU HIIHFWV DW  QJPO
whereas at 100ng/ml IFN-ȖZDVJHQHUDOO\DVWURQJHUVWLPXOXVWKDQ,/-17. 
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Interestingly, the response to IL-17 was greater with 10 ng/ml at 24h and 
100 ng/ml at 48 h. This could suggest that IL-17 does not necessarily act in 
a dose-dependent fashion. The fact that IL-17 effects were more marked at 
24 h suggests the role of Th17 earlier compared to Th1 effects. IL-17 also 
upregulated its own expression in NT2N which suggests a positive 
feedback mechanism.  
  
Stimulations with SP were additionally included to study reciprocal effects 
on IL-17 and its receptor expression as well as regulation of NK1R by SP. 
This can reflect a setting in the CNS upon neuronal injury during acute 
inflammation. From our previous results in T cells, SP expression is not as 
significant as NK1R upregulation on stimulation with Th17 and Th1 
cytokines. Neurons in this setting could be a significant source of SP that 
can influence inflammatory and immune effects, and in turn, upregulate the 
expression of IL-17R and IL-17 in neurons and other cells in MS lesions. 
Indeed, upregulation of IL-17R and IL-17 in NT2N by SP was confirmed. 
In our series SP 10-5 M upregulated IL-17RA, IL-17, and TAC1 whereas 
SP at 10-6 M resulted in reduced expression compared to the baseline 
values. SP at lower concentrations may indeed have a downregulatory 
effect on certain components of inflammation, whereas at high 
concentrations SP may be pro-inflammatory.  
 
The effects described above are examples of neuronal gene expression 
subject to regulation by IL-17. The main limitation of NT2N model in our 
Vilisaar, J. 
 108 
study is difficulty assessing neurotoxic effects of IL-17 in NT2N due to 
greater resistance of these cells to toxic stimuli. Cell viability was assessed 
by confocal microscopy with no differences observed in cell survival 
between stimulation conditions. This aspect of possible neurotoxic effects 
of IL-17 would need addressing in primary neuronal cultures. It may be 
additionally useful to study inflammatory mechanisms and neuronal 
survival in neuron-astrocyte co-cultures. Except for a few peculiarities, the 
above effects in NT2N have many similarities with the pattern of 
expression in peripheral blood mononuclear cells. The latter could serve as 
a more convenient experimental set-up for extrapolating aspects of 
immunological regulation in neurons. 
Vilisaar, J. 
 109 
 
6 Downregulation of NK1R in peripheral immune cells of multiple 
sclerosis patients in a relapse 
6.1 Introduction 
MS is an autoimmune disease characterized by CNS inflammatory 
demyelination and neuronal loss. Inflammation in MS is believed to be 
governed by Th17 and Th1 responses creating a cytokine and chemokine 
milieu that directs cellular mechanisms and feedbacks inflammation. This 
leads to perivascular infiltration of lymphocytes and macrophages and 
subsequent axonal demyelination. Local CNS cells (microglia, 
oligodendrocytes, astrocytes, neurons) play a role in developing 
inflammatory lesions as well as in remyelination. SP and other 
neuropeptides are involved in modulation of neuroimmune interactions by 
engaging with the inflammatory pathways. Recently, axonal loss has been 
regarded as an important hallmark of the disease present from the earliest 
stages. 
 
In MS, the state of the peripheral immune system is important in triggering 
relapses and determining disease activity. Peripheral immune cells directly 
invade the CNS in an acute MS relapse via breakdown of BBB. However, 
immune responses may also be propagated within the CNS itself by 
previously infiltrating and chronically activated peripheral immune cells 
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and/or chronically activated CNS resident cells, such as microglia (Bar-Or 
2008). In this case the inflammation becomes compartmentalized in the 
CNS and relatively independent of peripheral events (Bar-Or 2008). 
However, particularly in the early course of the disease and RR phase 
peripheral immune cells often guide CNS inflammatory responses, thus 
studying peripheral immune cell functions helps to elucidate processes in 
CNS inflammation. 
 
Immune status of MS patients can be influenced by a number of factors. 
Infections that induce cellular responses may trigger MS relapses, whereas 
for instance allergic states and parasitic infections activate Th2 responses 
and may appear protective. Trivial infections in MS patients, such as 
urinary tract infections, can trigger MS relapses, or like fever / high 
ambient temperature, can just worsen existing MS symptoms, termed 
pseudo-relapses. A thorough clinical assessment, excluding infections, 
assessing EDSS change etc, is important in relapse evaluation. 
Additionally, MS patients presenting with other co-morbidities or 
autoimmune diseases, the aspects of which influence the peripheral 
immune status, alter susceptibility to MS relapses. There are several other 
physiological and non-physiological factors, such as hormonal changes, 
that influence the occurrence of relapses. 
 
The immune status of MS patients can be influenced by several treatments 
that nowadays are becoming increasingly effective controlling relapse rate 
Vilisaar, J. 
 111 
and disease progression. At the time of this study, disease modifying 
treatments (DMT) mainly for RR type of the disease included E-interferons 
and glatiramer acetate. For severe and worsening disease, 
immunosuppressant regimens were used with mitoxantrone as a first-line 
treatment. For treatment of acute relapses high dose (1g/day) intravenous 
methylprednisolone (IVMP) is used. For IVMP treatment patients usually 
attend the Patient Investigation Unit (PIU) for 3 consequtive days; other 
dosing schemes may be used. Assessment prior IVMP treatment is 
important, infections are excluded by laboratory workup and Expanded 
Disability Status Scale (EDSS) determined on the basis of physical 
examination. An MS relapse as part of this study was defined as one or 
more new or previously observed neurological abnormalities consistent 
with the CNS demyelinating event for at least 24h. 
 
SP immunomodulatory role has been recently brought into attention as a 
potential target influencing immune responses in MS. There are several 
lines of evidence showing roles for SP in CNS demyelinating disease, 
however, in the mechanistic context of MS, the interactions of the main 
inflammatory pathways with SP are currently sparse and the evidence 
remains limited. An overview of the main pathologic features of MS and 
suggested roles for SP in MS have been covered in more detail in the 
literature review (section 2.2). Additional aspects of inflammatory 
mechanisms and cytokine networks have been covered in the introductory 
sections of the above experimental chapters. 
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The work in this chapter focusses on SP receptor in MS, measuring its 
expressional differences on the mRNA level in relapsing-remitting MS 
(RRMS) patients in a relapse and healthy controls. For this purpose 
peripheral whole blood cells were utilised. NK1R expression reflects the 
importance of SP signal and its receptive allowance in these cells enabling 
an indirect estimation of the role of SP as its primary ligand. As evidenced 
from previous chapters, the expression of SP itself would be more difficult 
to detect due to the variability of its expression, whereas NK1R expression 
is more reliable. We are comparing the experimental results with the 
SDWLHQWV¶ FOLQLFDO GDWDZLWK WKHKHOSRIZKLFK DUH VHHNLQJH[SODQDWLRQV WR
the findings. The expression of NK1R in MS has not been previously 
studied. 
 
As an acknowledgement for contribution to this chapter, part of the sample 
processing and RNA isolation was performed by Ms L Jean-Gilles. 
6.2 Methods 
6.2.1 Subjects and sample collection 
Patients for a donation of a blood sample were recruited solely at the 
Queen¶V 0HGLFDO &HQWUH 1RWWLQJKDP 8QLYHUVLW\ +RVSLWDOV 1+6 7UXVW
Nottingham (Ethics Committee Approval NS090102, valid for 10 years - 
please see Appendix C). 10 healthy controls and 11 relapsing-remitting MS 
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(RRMS) patients diagnosed with clinically definite MS according to the 
McDonald (2001, 2005) and Poser (1983) criteria were consented for the 
study. RRMS patients were recruited in a relapse when attending the PIU 
for IVMP treatment. They were assessed and consented for the study on 
PIU, a blood sample was obtained prior to the first dose of IVMP. No 
patient or control was recruited with a suspicion of a concurrent infection. 
Some patients were on DMT which was specified individually. No patient 
had received systemic corticosteroids or other course of 
immunosuppressants 6 months prior to the donation of a blood sample. 
Consent for blood donation was also obtained from healthy volunteers. The 
control and patient groups were age and sex matched. 
 
Upon meeting the study criteria a single blood sample from the consented 
VXEMHFWV ZDV FROOHFWHG YLD YHQHSXQFWXUH LQWR 3$;JHQH %ORRG 51$
tubes (PreAnalytix GmbH, UK) for stabilisation of intracellular RNA in 
peripheral whole blood. Tubes were kept at room temperature in an upright 
position for 4-6 h to allow stabilisation before transferring them to -&
for 24 h and subsequently storing at -& 
6.2.2 Extraction of total-RNA from whole blood 
2QWKHGD\RIH[WUDFWLRQ3$;JHQHWXEHVZHUHWKDZHGLQDZLUHUDFNDW
DPELHQWWHPSHUDWXUH&«&IRUDSSUR[LPDWHO\K%ORRd samples 
were processed following the instructions of the PAXgene Blood RNA 
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Kit  (PreAnalytix GmbH, UK) for isolation and purification of intracellular 
RNA from whole blood.  
Briefly, after centrifuging PAXgene tubes, pellets were washed with 
RNase-free water, resuspended in buffer (BR1) and incubated for 10 min 
with a binding buffer (BR2) and proteinase K at 55 qC. The lysate was 
processed through Shredder spin columns, absolute ethanol was added to 
the flow-through fraction which was then processed through PAXgene 
RNA spin columns. Flow-through was discarded and processing columns 
were washed through with the washing buffer (BR3), thereafter treated 
with DNase I in the DNA digestion buffer (RDD) and washed again. RNA 
was collected by treating spin columns with the elution buffer (BR5). The 
elute was incubated at 65 qC for 5 min to denature the RNA for 
downstream applications. 
The RNA concentration was determined at 260 nm by NanoDrop ND-
1000 spectrophotometer (Nanodrop Technologies, USA). Purity was 
assessed by measuring the 260/280 nm ratio, only samples in the range 
1.70-1.95 were used. 
6.2.3 Reverse transcription 
The first step of reverse transcriptase reaction was initiated on 0.5 Pg of 
total RNA (0.1 Pg/Pl) incubated with 1 Pl of random hexamers (0.5 Pg/Pl) 
(Promega, USA) in a volume of 15 Pl with nuclease-free water at 70 qC for 
5 min. The microcentrifuge tubes were kept on ice until the following 
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reverse transcription step whilst adding 5 Pl 5x MMLV reverse 
transcriptase buffer (Promega, USA), 1.25 Pl nucleotides (10 mM dATP, 
dCTP, dGTP, dUTP) (Promega), 0.5 Pl RNasin ribonuclease inhibitor 
(Promega), 1 Pl MMLV reverse transcriptase (Promega) and 2.25 Pl 
nuclease-free water (Sigma-Aldrich, UK) to a final volume of 25 Pl. The 
mixture was incubated at 42 qC for 1 hour, subsequently diluted to 100 Pl 
with nuclease-free water for the qPCR step or storage at ±20 qC. 
6.2.4 Quantitation of NK1R and TAC1 mRNA transcripts 
Quantitative real-time PCR was carried out to assess NK1R and TAC1 
mRNA abundance using the SYBR Green fluorescence method as 
specified by the manufacturer (Stratagene, USA). Relative standard curve 
method (AppliedBiosystems 1997) was used with standards obtained by 
pooling equal aliquots of undiluted cDNA from each sample. The primers 
for NK1R, TAC1, internal standard E2MG, and the reaction conditions 
were used as in section 4.2.6. For all reactions, dissociation profiles were 
obtained to ensure that genomic amplification products were not detected.   
6.2.5 Collection of medical data 
Patient medical records were used to obtain the following information: 
demographics, onset of first MS symptoms, time of diagnosis, OCB 
presence, distinct features on MRI (lesion distribution, T2 lesion load and 
Gd+ lesions), routine autoantibody panel (including anti-nuclear, anti-
thyroid peroxidase, anti-mitochondrial, anti-gastric parietal cell, anti-
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smooth muscle and anti liver kidney microsomal antibodies) with positive 
titres, other positive serum or CSF immunology, history and severity of 
neuropathic pain, medications used, last course of steroids or other 
immunosuppressants prior to the blood sample, previous relapse prior to 
the current presentation, other relevant medical history. For disability 
assessment Kurtzke EDSS was used. EDSS training and certification was 
obtained via Neurostatus, Basel, Switzerland, e-Test at 
http://www.neurostatus.net (Level C). The following scale was used for 
assessing neuropathic pain levels: 0 -  no pain, 1 ± mild pain, 2 ± moderate 
pain, 3 ± severe pain. Pain belonging to any of the neuropathic pain 
categories (definite, probable, possible) was rated as above.  
Throughout the study Data Protection Act 1998 was followed. Additionally, 
in the subsequent analysis data processing was run anonymously. 
Experimental data was kept blinded from the medical data until the final 
data analysis step. 
6.2.6 Statistical analysis 
For the analysis Mann-Whitney, Kruskal-Wallis tests, chi-squared statistics 
DQG6SHDUPDQȡFRUUHODWLRQZHUHXVHG 
6.3 Results 
The summary of the descriptive data of MS patients and controls is 
presented in Table 6.1. 
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 MS Patients Controls 
Number of subjects 11 10 
Mean age +/- SDi 42.8 +/- 8.7 40.6 +/- 10.6 
Female/Male ratio 8/3 7/3 
Mean Time from onset of first 
symptoms 
4.3 +/- 4.9 NA 
Mean EDSSii +/- SD 3.6 +/- 2.0 NA 
Number of patients on DMTiii 
Neuropathic pain present  
2 
9 
NA 
NA 
i
 Standard Deviation 
iiExpanded Disability Status Scale 
iiiDisease Modifying Treatment 
 
Table 6.1. The summary of the main characteristics of the patient and 
control groups compared in the study. 
 
7KHUHODWLYHH[SUHVVLRQ1.5ȕ0*LQSHULSKHUDOZKROHEORRGFHOOVZDV
compared in RRMS patients and healthy controls. NK1R in the peripheral 
blood was significantly less expressed in the MS group than in the control 
JURXS 7KH PHDQ 1.5ȕ0* P51$ UDWLR ZDV 1.483 +/- 3.249 in MS 
patients as compared to 23.686 +/- 24.604 in healthy volunteers (p=0.000) 
(Fig 6.1). 
 
Vilisaar, J. 
 118 
0
10
20
30
40
50
60
70
NK
1R
/b
2M
G
Patients                                    Controls
Patients
Controls
 
 
)LJXUH1.5P51$DEXQGDQFHQRUPDOLVHGZLWKȕ0*DUELWUDU\XQLWV
in peripheral whole blood cells from 11 RRMS patients and 10 healthy 
controls. 
 
Age was not significantly associated with NK1R expression neither in 
patients nor in controls, despite the strong trend in the latter (p=0.058) with 
downregulation of NK1R with increasing age. No gender-related 
differences were found in NK1R expression, however, in the control group 
there was some tendency for less NK1R expression in females. With 
regards to clinical features, no differences were found in NK1R expression 
between OCB positive (OCB+) and OCB- patients and the autoantibody 
positive and negative patients. NK1R expression did not correlate with the 
disease duration and no correlation was found between NK1R expression 
and disability. For descriptive purposes of the RRMS subgroups it should 
be noted that no significant differences were seen between OCB+ and 
1.48 23.68 Mean 
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OCB- patients with regards to EDSS and other clinical characteristics. 
Comparison of patients with a normal autoantibody screen with patients 
with other positive autoantibodies (at least one positive autoantibody titre) 
showed no distinction in other clinical features or NK1R expression. In the 
autoantibody positive group a slight trend was seen towards higher 
disability, assessed by the EDSS. Importantly, NK1R expression did not 
correlate with the level of neuropathic pain in MS. Two of the 11 RRMS 
patients were on DMT at the time and in these two cases NK1R mRNA-
level expression was similar to other patients showing no different 
tendencies.  
 
([SORUDWRU\ H[SHULPHQWV ZHUH DOVR FRQGXFWHG WR VWXG\ 7$&ȕ0*
mRNA level expression in 3 patients and 3 controls in order to assess the 
differences in NK1R and TAC1 expression. The results show distinct 
downregulation of NK1R in these 3 patients, whereas TAC1 expression 
was low in both patient and control groups (Fig 6.2). Only a small 
difference can be observed in TAC1 expression between MS patients and 
healthy controls, however, at present this cannot be attributed any 
significance.  
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Figure 6.2. NK1R and TAC1 mRNA abundance normalised tR ȕ0*
(arbitrary units) in peripheral whole blood cells of 3 MS patients and 3 
healthy controls +/- SEM. 
 
6.4 Discussion 
The results refer to the whole population of cells in peripheral blood and 
thus may raise questions about whether they reflect a targeted cell function. 
Among other constituents, the whole blood includes leukocytes, virtually 
the only nucleated cells in human peripheral blood, of which 
approximately 50-60 % are neutrophils and 25-30% lymphocytes. 
Although SP is also involved in neutrophil activation, when comparing 
whole blood of MS patients and healthy controls, the main differences are 
expected to arise from the lymphocyte population. Particular care has been 
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taken not to include patients and controls with any suspected infection. No 
ex vivo stimulation conditions as additional variables are used in this 
method. Analogous experiments addressing SP or NK1R expression in 
human peripheral whole blood have not been published to date. 
Additionally, no studies have been published on NK1R expression in MS 
patients. 
 
NK1R expression in peripheral blood immune cells can be considered 
more informative than SP expression for reasons specified in Chapter 4. 
The results show highly significant differences in NK1R mRNA 
abundance between patients and controls with strong downregulation of 
NK1R in an MS relapse. TAC1 was much less expressed in both groups, 
which is expected as peripheral blood cells are not a major source of SP. 
SP is the main ligand for NK1R, however, other tachykinins as alternatives 
for NK1R binding may play a role. Focussing on NK1R also reflects 
reception of other tachykinins, such as hHK-1, which is another recently 
uncovered NK1R ligand, particularly in lymphocytes and cells of 
monocyte lineage. Although TAC1 exon 7 encodes other tachykinins 
originating from alternative splicing of TAC1 gene, the issue of not 
addressing other tachykinins in this thesis is one of the main limitations of 
the study. 
 
It is important to address the issue of drawing conclusions on the results 
considering the role of SP in MS. Assumptions allowing conclusions on SP 
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role in MS are based on evidence of its role in demyelinating disease, such 
as demonstrated in direct in vivo studies in EAE. As another aspect, NK1R 
expression in lymphocytes and cells of monocyte lineage in peripheral 
blood is likely different compared to the CNS, where different cell types 
express SP and higher amounts of SP are available. The model does not 
fully reflect the role of SP in peripheral immune cell function applicable in 
the CNS setting, where additionally the immunological role of SP could be 
different, including possible SP concentration-dependence, as seen in the 
previous chapter, and various co-effects with other mediators. Additionally, 
SP receptor isoform expression has been shown different in these tissues 
(Caberlotto et al. 2003). Thus, studying NK1R expression in peripheral 
whole blood as an aspect of CNS inflammation only allows limited 
conclusions. Nevertheless, some indirect conclusions are possible on the 
immune cell perspective in an acute MS relapse which results in invasion 
of these cells into the CNS.  
  
The mechanism for NK1R downregulation in MS is not clear. Decreased 
NK1R expression in blood of MS patients may represent an effect of 
specific inflammatory cytokines upregulated in MS. Our results are 
consistent with a single published study showing reduced NK1R 
expression in IFN-Ȗ ,/-ȕ71)-ĮVWLPXODWHGPDFURSKDJHV(Berger et al. 
2007). These pro-inflammatory cytokines which play a role in MS 
pathogenesis may have a role in downregulating NK1R also in our patients. 
The inflammatory mechanism is one of the most likely explanations to our 
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findings in an acute MS relapse. Additionally in Chapter 4, our NK1R 
promoter level results in Jurkat cells are consistent with the findings by 
Berger with IL-12 and IFN-Ȗ VKRZLQJQRDFWLYDWLRQRI WKHSURPRWHUEXW
rather a tendency for NK1R downregulation. Also IL-18 alone exerted a 
downregulatory effect in NK1R surface staining results in T blasts. 
However, further experiments would be necessary to test these 
inflammatory effects on NK1R expression.  
 
Our findings refer to SP regulation that could be important in MS 
pathogenesis. Th1 cytokines have been shown in the past to be pro-
inflammatory, however, their recently uncovered inflammation limiting 
properties may be important in regulation of SP effects. Th1 cytokines 
downregulating NK1R may be one of the mechanisms limiting SP pro-
inflammatory effects at high SP concentrations, such as may occur upon 
neuronal injury. On the contrary, Th17 cytokines appear important in 
upregulating NK1R as seen in Chapter 4. That in fact, may contribute to 
the acute inflammation in the early stages when Th17 responses are 
prevalent. At lower concentrations, without neuronal injury, SP may 
exhibit immunosuppressive (Chen et al. 1996) and neuroprotective effects 
(Raffa 1998; Amadoro et al. 2007) and upregulation of NK1R in these 
settings may be beneficial. This supposition would require further studies.  
 
It can be stated that there is a difference in NK1R expression in RRMS and 
healthy controls, however, it is not possible to confirm whether it is due to 
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inflammatory activity, although it seems the likely explanation. To address 
this question additional experiments would be needed looking at NK1R 
expression in different types of MS and RRMS comparatively in a relapse 
and remission. Larger numbers of recruitment are necessary to elucidate 
these differences. For the validity of the method (uniformity of the study 
groups, reducing other variables) and due to time constraints only RRMS 
patients in an acute relapse were used in this study. Based on the 
inflammatory role of SP, NK1R downregulation would be expected to be 
less significant in progressive types of MS. In the current study, no 
inflammatory and immune markers allowed associations with differences 
in NK1R expression within the relapsing patient group which can be due to 
inflammatory activity. 
 
Other explanations, besides those directly inflammatory, could be found 
for NK1R downregulation in MS. NK1R as a G-protein coupled receptor is 
easily internalised and the expression rapidly downregulated after receptor 
activation. One such consideration for the receptor response in MS patients 
is the presence of neuropathic pain as a common symptom in MS. It is a 
theoretical possibility that higher pain levels may have downregulated 
substance P receptor. Neuropathic pain mechanisms are complex, in MS 
they usually arise as a direct consequence of demyelinating lesions in 
somatosensory pain pathways (Treede et al. 2008). Additionally being very 
subjective, pain levels are variable in MS and are not associated with the 
disease activity. Nociceptive pains, resulting from activation of peripheral 
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afferents, may often co-exist. Nevertheless, no stress hormones or other 
agents have been previously demonstrated in association with pain 
affecting NK1R expression in peripheral blood. 
 
To address the issue about peripheral blood NK1R expression and pain 
being possibly associated, we have compared NK1R expression with the 
severity of neuropathic pain in the patient group. The current results were 
homogeneous with regards to NK1R expression as different levels of pain 
were not affecting peripheral blood NK1R expression. An association of 
NK1R with the level of pain thus appears a less likely explanation in 
peripheral immune cells, supporting the inflammatory mechanism in 
NK1R downregulation. It may, however, be the case that in the context of 
acute inflammatory activity that distinction cannot be reliably made. 
Additionally age and gender related differences in the MS group may not 
have been apparent due to prevailing inflammatory activity. Hence, in the 
future studies pain levels are an important consideration in the study design. 
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7 Conclusions 
 
Cytokine-like properties of SP and its role in immunogenic inflammation is 
a recent recognition on which still limited evidence is available and very 
little has been published on humans. SP effects in immunogenic 
inflammation can be shown as modulatory, implemented by a number of 
mechanisms, including inflammatory cytokine induction. Reciprocal 
interactions exist in expression and effects of SP and its receptor with 
various other inflammatory mediators and their pathways. In this thesis we 
have been studying SP and NK1R role from the perspective of 
autoimmune inflammation of MS. We have focussed on SP role 
particularly in relation to Th17 and Th1 pathways, as the main drive of SP 
pro-inflammatory properties. In the four experimental chapters we covered 
induction of inflammatory cytokines by SP in PBMC (Chapter 3), 
dependence of SP and NK1R expression on inflammatory stimuli in T cells 
(Chapter 4) and NT2N (Chapter 5), and the expression of NK1R in RRMS 
patients and controls (Chapter 6). The main findings of these chapters are 
concluded below. 
 
In Chapter 3, we studied the expression of various inflammatory cytokines 
in response to SP in PBMC. In particular, we focussed on SP induction of 
IL-12 and IL-23 as the key cytokines in Th1 and Th17 pathways 
respectively. Treatment of PBMC with SP showed marked increase in the 
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relative quantity of IL-12/IL-23p40, IL-23p19 and IL-12p35 mRNA in 
these cells indicating that SP receptor can signal IL-23 and IL-12 subunit 
induction. Protein-level results were not confirmatory as protein level 
expression may require activated cells or additional co-activating factors. 
The findings support SP ability to enhance Th17 and Th1 responses with a 
favour to Th17 induction. As an additional finding that would bear 
importance in further studies is toxicity of CP-96345 and CP-96344 at 
concentrations 10-4 M and higher. We also observed interesting 
interactions of CP-96345 and CP-96344 with LPS effects that would need 
further elucidation. In particular, the relationship between SP and TLR will 
need to be further explored. 
 
In Chapter 4 we investigated the opposite ± the regulation of SP and its 
receptor expression by Th17 and Th1 cytokines in T cells. IL-23 
significantly upregulated both TAC1 and NK1R on the mRNA level, 
whereas induction by IL-12 was not significant. These effects on NK1R 
were confirmed on a protein level with NK1R surface staining, and 
promoter studies in which IL-23 differential effects compared to IL-12 
were most pronounced. IL-23 effects were partially mediated via induction 
of IL-17, whereas IFN-J did not mediate IL-12 effects. NK1R was 
significantly upregulated also by IL-17, while IFN-J had no significant 
effects. We saw that IL-23 effects were prevalent at earlier stages than the 
effects by IL-12. Th17 stimuli in our series were important inducers of 
NK1R and TAC1 supporting dependence of SP and NK1R expression in T 
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cells on inflammatory stimuli. The findings suggest SP involvement in 
Th17 and less in Th1 pathway effects. 
 
As part of Chapter 5 we showed that neuronal NK1R expression was 
subject to regulation by IL-17; TAC1 was considerably less upregulated. 
IL-17 and IFN-ȖHIIHFWVZHUHFRPSDUDEOHERWKVKRZLQJRSWLPDOHIIHFWVDW
10 ng/ml. IL-17 effects are likely more important earlier at 24h compared 
to IFN-ȖSUHYDLOLQJWUHQGDWK63-5 M upregulated IL-17R, IL-17 and 
TAC1 but not its own receptor in NT2N. With these results we 
demonstrated that IL-17 can regulate NT2N gene expression via its 
receptor, having shown effects via IL-17RA functional expression in these 
cells. Further studies are needed for structural confirmation and elucidating 
signalling of IL-17R in NT2N. The above effects have important 
implications in neuroinflammatory conditions, however, IL-17 possible 
neurotoxicity would need addressing in primary neurons. The findings 
indicate that neurons are involved in immune interactions involving SP and 
Th17 pathway. 
 
In Chapter 6, we compared relapsing RRMS patients with healthy 
volunteers to study differences in NK1R mRNA-level expression between 
the groups. NK1R was significantly downregulated in peripheral blood of 
RRMS as compared to healthy controls. Experiments on TAC1 expression 
showed much lower levels in relative quantity of SP precursor mRNA in 
both patients and controls with no significant differences between the 
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groups. The most likely explanation for NK1R downregulation in the 
patient group is the inflammatory mechanism. No immune and other 
inflammatory markers allowed distinctions in expression of NK1R, which 
can be explained with the inflammatory activity in an acute relapse. 
Further studies are needed to investigate NK1R expression differences 
between different types of MS and RRMS in relapse and remission. Pain 
was not associated with the level of NK1R expression, nevertheless, in 
future study design this has to be considered. 
 
As one of the concluding findings in our study, SP pro-inflammatory 
activity is associated with the Th17 pathway. This is a novel association as 
previously SP has been shown to be linked with Th1 activities, which may 
be explained by the relatively recently uncovered Th17 role. As previous 
studies were done in murine models it is unclear how Th17 would compare 
with Th1 in mice in these experimental settings. According to our findings, 
Th17 and Th1 cytokines in humans seem to have differential effects on 
expression of SP and NK1R both in peripheral immune cells and less in 
NT2N. In neurons NK1R expression is more dependent on inflammatory 
stimuli than SP expression. Although Th1 cytokines are having mild 
effects in our experiments, Th17 far outweigh Th1 effects in T cells. Th17 
pro-inflammatory pathway is communicated by SP by NFNB signalling. 
Hence, as results from this thesis suggest, a proportion of SP pro-
inflammatory properties are implemented via Th17 pathway activation and 
less so via Th1. As a limitation to this, we have not tested all Th1 
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cytokines, thus final conclusions need to be cautious. For example, it is not 
possible to compare how the cytokines used in our study compare with IL-
 HIIHFWV ZKLFK DOVR DFWV YLD 1)ț% and has been previously reported to 
induce SP and NK1R protein-level expression (Guo et al. 2004). Of note, 
IL-1 may also be a T cell cytokine and in our previous experiments has 
been induced by SP in PMA/ionomycin activated T cells (Chopra and 
Constantinescu, unpublished observations).   
 
Reciprocal interactions of SP with other cytokine networks is one of the 
other important findings of the study. As studied in the first two 
experimental chapters, mutual regulation is evident in relation to the Th17 
pathway. Previously, IFN-J immunoregulatory circuit and other SP 
paracrine and autocrine interactions involving mainly Th1 pathway have 
been demonstrated (Pascual et al. 1990; Blum et al. 1993; Castagliuolo et 
al. 1997; Cioni et al. 1998; Weinstock et al. 1998). In our studies little 
evidence for the induction of Th1 cytokines and their reciprocal induction 
of SP was seen in the human system. On occasions, Th1 cytokines even 
seemed to exert limiting effects. It is possible that SP pro-inflammatory 
interactions with Th17 pathway prevail in humans. However, prior studies 
focussing mainly on Th1, predominantly in murine models, allows limited 
conclusions on circuits involving Th17 versus Th1. For the future studies it 
would be of interest testing SP induction of cytokines, such as IL-17 and 
IFN-J, in parallel. Bi-directional induction seen in our results serves 
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feedback mechanisms and supports SP role modulating propagation of 
immune responses.  
  
Preconditioning of cells is important for optimal SP effects, and similarily, 
priming of cells with SP has been shown important for different cytokine 
effects. Pre-activation seems to change responsiveness of cells to particular 
inflammatory stimuli, in some circumstances co-activation is needed for 
eliciting downstream signalling events. Conditioning of cells has been 
shown in a number of different inflammatory models previously. For 
example, LPS preactivated monocytes have been shown to have increased 
response to SP (Laurenzi et al. 1990), SP has been shown to mediate and 
enhance release of different cytokines from macrophages and other 
immune cells (Blum et al. 1993; Berman et al. 1996; Castagliuolo et al. 
1997), enhance TNFD secretion from pre-activated neuroglial cells (Luber-
Narod et al. 1994), IL-2 release from activated T cells (Calvo et al. 1992) 
etc. This partly also explains inconsistencies in protein- and mRNA-level 
expression as additional factors and co-factors downstream, regulating 
post-transcriptional events seem important. This suggests how SP protein-
level induction is controlled in inflammatory settings.  
 
The effects of SP may be concentration dependent, i.e. at high 
concentrations SP may be pro-inflammatory, whereas at low 
concentrations it may show anti-inflammatory effects. There are some 
suggestions for the latter also from earlier reports (Chen et al. 1996). Hints 
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to SP dichotomic effects were seen in Chapter 5 and Chapter 3. We found 
that the effects on IL-12 subunit production with SP 10-12 M as compared 
to 10-6 M was occasionally lower than baseline in PBMC, and SP 10-6 M 
has shown downregulatory effects compared to 10-5 M on various genes in 
NT2N. This may suggest that in neurons the effects by SP are possibly 
different than in PBMC, which can be contributed by higher concentrations 
of SP in the CNS and expression of different SP receptor isoforms in these 
tissues. The effects in NT2N on IL-17 and IL-17RA downregulation are 
pointing to inflammation limiting effects, whereas in PBMC the effects are 
more distinct with Th1 and Th17 cytokines. These effects of SP may prove 
important in CNS inflammatory settings, however, as the observations are 
statistically not significant, it currently remains on a speculative basis. 
Additionally, no evidence was presented in our study on SP 
neuroprotective features as these were not possible to study in NT2N. 
Nevertheless, we did not note a difference in NT2N survival ability in 
different neuronal culture conditions. Hence SP, classically known for its 
pro-inflammatory effects, may function as a cytokine that helps to regulate 
the balance of the inflammatory arms also limiting autoimmune damage. 
The possible dual nature of SP in inflammation would need further studies. 
 
As a novel finding from the thesis, neurons react actively to Th17 stimuli 
which regulates their SP and NK1R expression. The finding assumes 
expression of IL-17R on them through which these effects are mediated. 
Functional evidence is supporting this, however, further experiments on 
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the protein level are necessary to confirm IL-17R structurally. The findings 
indicate that neurons participate actively in immune responses and may 
modulate these by neuroimmune feedback. SP has a role communicating 
these interactions. The results support the importance of SP 
immunomodulatory role in CNS inflammation. Th17 responses seen in 
neurons reveal a different perspective on neuronal response to autoimmune 
inflammation. Further studies are needed to elaborate the findings and 
study signalling pathways. The results have also important implications 
with regards to sequelae leading to inflammatory neurodegeneration and 
possible targets for neuroprotection.  
 
As a general comment to the findings, being aware of other tachykinins, 
such as hemokinin-1, acting on NK1R, is important. This is particularly 
relevant in peripheral immune cell function. This thesis has focussed 
mainly on the role of SP as the NK1R primary ligand. No experiments 
were done where intermediary steps were used that depended on 
subsequent induction of SP or other tachykinins. TAC1 gene gives rise to 
different tachykinins as a result of four different splice variants, whereas 
exon 7 is included in all of these. Hence, our TAC1 mRNA-level results 
reflect also the expression of other tachykinins. However, this is important 
to consider in transferring conclusions to in vivo settings. This may also 
account for possible differences in role of SP on immune function in 
peripheral blood and in the CNS. Thus, focussing only on SP may appear 
not that informative than studying NK1R expression in these settings, and 
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NK1R does not reflect only on SP reception.  Not testing comparatively 
other tachykinins can be considered one of the limitations of the study, 
however, for reasonable experimental design and aims purposes this was 
inevitable.  
 
As a conclusion, our study has attempted to shed light on involvement of 
SP in autoimmune inflammation with the focus on the human system and 
CNS inflammation. Pertinent to these settings, the role of SP can be best 
summarized as of a pleiotropic immune regulator. SP has probably 
underrecognized role in CNS inflammation where it serves as a 
neuroimmune regulator. In vivo evidence has previously shown SP and 
NK1R pathogenic role in EAE. In humans, SP participates in a range of 
pro-inflammatory cytokine networks, particularly in Th17 pathway 
interactions. Its modulation of immune activities is characterized by mutual 
regulation and co-effects with other mediators. SP release with both its 
neurogenic and immunogenic actions may serve as an amplification 
mechanism that perpetuates the inflammatory cascade (Bozic et al. 1996). 
Its signalling involves activation of NFNB, which is behind the regulation 
of various inflammatory genes, explaining SP regulation of chemotaxis and 
other inflammatory mechanisms. The overall picture involving SP roles, 
however, is complex and its multiple facets yet remain to be elucidated. 
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9 Appendices 
9.1 Appendix A. Data analysis for real-time qPCR experiments 
The experiments employed Mx4000 multiplex qPCR instrument 
(Stratagene, USA) and SYBR Green detection system (Stratagene, USA). 
The experiments were performed as two-step quantitative reverse 
transcriptase PCR reactions, i.e. the reverse transcriptase and qPCR steps 
were run as separate reactions. The following analysis was routinely 
performed for each qPCR experiment. 
 
Following qPCR data collection raw fluorescence values and amplification 
plots were analyzed, any RXWOLHUV ZHUH H[FOXGHG ³1R WHPSODWH FRQWURO´
(NTC) plots, three of which were included in each experiment, were 
screened for contamination, primer dimer formation, other non-specific 
increase in the fluorescence signal. For amplification plots the baseline 
was set such that linear contributions to the fluorescence were subtracted 
(only range of cycles giving exponential growth of signal contributed). 
The threshold cycle (Ct) was adjusted as necessary to the exponential or 
near-exponential phase of all samples. 
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Standard curve 
Relative standard curve method was used as described by Applied 
Biosystems (AppliedBiosystems 1997). As specified in the experimental 
chapters, the standard curve was constructed based on Ct values of serial 
dilutions (usually 1:1, 1:2, 1:5, 1:10, 1:20) from the pool of cDNA made 
up of equal aliqots from each analyzed sample.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig A1. Example of the standard curve output graph. Ct values of the 
standards are plotted against log of the initial template quantity. The 
linearity is expressed as Rsq (R2 or Pearson Correlation Coefficient), the 
efficiency (E) is derived E = 10 (-1/slope)-1. Rsq= 0.997, E= 107.3%. 
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Example of standard calculations for finding mRNA abundance for 
samples 
For the above example in Fig A1 the standard curve equation can be 
expressed as follows: 
 
Y= -3.159 log X + 33.82 
 
where Y is the Ct value of an individual sample; X is the mRNA 
abundance of the transcript (arbitary units). 
 
 
 
 
 
 
 
 
 
 
 
Figure A2. Amplification plots of the unknowns. Ct value correlates to the 
amount of starting concentration of the target mRNA which can be derived 
from the standard curve and after normalization can be compared between 
different stimulation conditions.  
Vilisaar, J. 
 166 
 
For the qPCR all samples of cDNA were loaded in triplicates for both 
standards and unknowns and the three Ct values for each 
standard/unknown were averaged. Using the above standard curve the 
mean Ct value was applied in the formula to find the mRNA abundance of 
the unknowns: 
 
 Y ± 33.82 
logX= 
-3.159 
 
Additionally, dissociation curve analysis was included in each experiment 
to exclude genomic DNA amplification and formation of primer dimers. 
This is particularly important with SYBR Green system due to non-
specific binding of the dye to a double-stranded product. Special care was 
taken to ensure that single melting curves at right temperatures were 
obtained for each sample.  
 
The values of individual mRNA abundance were standardized with the 
corresponding values of the housekeeping gene as specified in the 
chapters. For the above example of NK1R expression, E2-microglobulin 
gene was used as an housekeeping gene. The same procedure as described 
above was run for the housekeeping gene on the same plate and the ratios 
of the gene of interest/ housekeeping gene transcribed mRNA abundance 
were calculated. 
Vilisaar, J. 
 167 
 
 
 
 
 
 
 
 
 
 
 
 
Fig A3. Dissociation curve, as in an example for NK1R, depicts the negative 
first derivative of raw fluorescence plotted against increasing temperature. 
Single homogeneous melting curves for each well were obtained, indicating 
specific amplification. 
 
The final results, expressed in ratios, were comparable between 
stimulation conditions allowing control for differences in RNA isolation, 
reverse transcription reaction efficiency and other sample to sample and 
experiment to experiment technical variability.  
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9.2 Appendix B. The McDonald Criteria (2010) for Diagnosis of MS 
 
 
 
(Polman et al. 2011) 
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9.3 Appendix C.The Ethics Commitee approval for patient recruitment 
 
